WO2023033681A1 - Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) - Google Patents
Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) Download PDFInfo
- Publication number
- WO2023033681A1 WO2023033681A1 PCT/RU2022/050272 RU2022050272W WO2023033681A1 WO 2023033681 A1 WO2023033681 A1 WO 2023033681A1 RU 2022050272 W RU2022050272 W RU 2022050272W WO 2023033681 A1 WO2023033681 A1 WO 2023033681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triazole
- ethanamine hydrochloride
- disorder
- phenyl
- optionally substituted
- Prior art date
Links
- 108090000946 Trace amine-associated receptor 1 Proteins 0.000 title abstract description 43
- 102000004406 Trace amine-associated receptor 1 Human genes 0.000 title abstract description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 208000035475 disorder Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 230000001404 mediated effect Effects 0.000 claims abstract description 17
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 8
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 8
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 7
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 6
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims description 37
- -1 methoxy, ethoxy, propoxy, butoxy Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 229910052717 sulfur Chemical group 0.000 claims description 7
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims description 5
- 206010013654 Drug abuse Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 239000001301 oxygen Chemical group 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000017164 Chronobiology disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 206010057852 Nicotine dependence Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 4
- 206010001584 alcohol abuse Diseases 0.000 claims description 4
- 208000025746 alcohol use disease Diseases 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000005265 energy consumption Methods 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 230000013632 homeostatic process Effects 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 230000007958 sleep Effects 0.000 claims description 4
- 208000020685 sleep-wake disease Diseases 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 101000890887 Homo sapiens Trace amine-associated receptor 1 Proteins 0.000 claims 2
- 102100040114 Trace amine-associated receptor 1 Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000000926 neurological effect Effects 0.000 abstract description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 186
- 230000015572 biosynthetic process Effects 0.000 description 45
- 238000003786 synthesis reaction Methods 0.000 description 45
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 238000000034 method Methods 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 102000011829 Trace amine associated receptor Human genes 0.000 description 8
- 108050002178 Trace amine associated receptor Proteins 0.000 description 8
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 102000016981 Trace amine receptors Human genes 0.000 description 5
- 108070000027 Trace amine receptors Proteins 0.000 description 5
- 150000001411 amidrazones Chemical class 0.000 description 5
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000001730 monoaminergic effect Effects 0.000 description 5
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical class O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 150000003852 triazoles Chemical class 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000003227 neuromodulating effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 229960003732 tyramine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- RGHNJXZEOKUKBD-NRXMZTRTSA-N (2r,3r,4r,5s)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-NRXMZTRTSA-N 0.000 description 1
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- PLGUMYDTHLRXMR-UHFFFAOYSA-N 3-aminopropanehydrazide Chemical compound NCCC(=O)NN PLGUMYDTHLRXMR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- KAEGGIFPLJZUOZ-UHFFFAOYSA-N Renilla luciferin Chemical compound C1=CC(O)=CC=C1C(N1)=CN2C(=O)C(CC=3C=CC=CC=3)=NC2=C1CC1=CC=CC=C1 KAEGGIFPLJZUOZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101150008710 TAAR1 gene Proteins 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003379 hyperdopaminergic effect Effects 0.000 description 1
- 230000003528 hypoglutamatergic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950002454 lysergide Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000006422 monoaminergic transmission Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- OSDZHDOKXGSWOD-UHFFFAOYSA-N nitroxyl;hydrochloride Chemical compound Cl.O=N OSDZHDOKXGSWOD-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Definitions
- the present invention relates to substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines or pharmaceutically acceptable salts thereof exhibiting properties of a trace amine receptor (TAAR1) agonist, a method for production thereof, a pharmaceutical composition on their basis and a use thereof.
- TAAR1 trace amine receptor
- Trace amines such as ⁇ -phenylethylamine (PEA), tyramine, tryptamine and octopamine are structurally similar to classical monoamines and play an important role in invertebrate physiology, but their functions in the body of mammals, where they are present in trace amounts, remain unknown. Determining the role of these amines and their receptors in mammalian physiology would explain many enigmas in pathology and pharmacology of monoaminergic synaptic transmission [Sotnikova et al., 2008]. In general, TAs are present in the CNS and function in parallel with monoaminergic pathways. TAs are structurally related, co- localized and recovered with biogenic amines and neurotransmitters.
- PEA ⁇ -phenylethylamine
- tryptamine tryptamine
- octopamine are structurally similar to classical monoamines and play an important role in invertebrate physiology, but their functions in the body of mammals, where they are
- TAs are thought to posses the neuromodulatory functions of classical neurotransmitters such as dopamine, serotonin and norepinephrine which levels are affected by all antidepressants and antipsychotics currently being used in clinical practice.
- Dysfunctions in TA physiology have long been associated with schizophrenia and mood disorders.
- Increased urine PEA levels, changes in tryptamine and tyramine metabolism, and changes in enzymes involved in the synthesis and catabolic pathways of these amines have been shown to be associated with schizophrenia.
- PEA hypothesis was developed to explain causes underlining depression development which postulates that PEA deficiency is related to endogenous depression: pilot studies have shown that the use of this amine or its precursor reduces symptoms of depression.
- TAAR1 is the most investigated receptor among TAARs which represents a new target for pharmacology of a wide range of mental, neurological and metabolic disorders, and substances acting on TAAR1 are already on the stage of clinical trials [Revel et al. 2011; Revel et al.2012; Berry et al., 2017].
- TAAR1 is a proven target for endogenous TAs.
- the TAAR1 gene is expressed in brain structures associated with mental disorders, in particular in those key areas where modulation of dopamine (ventral tegmental region) and serotonin (brainstem raphe nucleus) occurs, as well as in the amygdala, hypothalamus, nucleus accumbens, entorhinal and frontal cortex and subiculum. Therefore, even if the TA function is not impaired, neuromodulatory effects on monoaminergic pathways could predictably lead to improved mental health.
- TAAR1-KO mice TAAR1-KO mice
- Their use in studies has shown that TAAR1 agonists should be effective in the treatment of mental and a number of other disorders such as schizophrenia, depression, ADHD, drug abuse, Parkinson’s disease, sleep disorders by acting either directly or indirectly on monoaminergic pathways [Revel et al.2011; Revel et al.2012].
- TAAR1 expression levels were also found in the pancreas, stomach and intestines, and preclinical studies have shown the efficacy of TAAR1 agonists in metabolic disorders such as obesity and diabetes. TAAR1 expression was also shown in leukocytes suggesting the involvement of this receptor in immunological processes [Lam et al., 2015]. Searches for new TAAR1 receptor modulators and their use as agents for the treatment of mental disorders, cognitive disorders, metabolic disorders, neurological and neurodegenerative diseases are very relevant.
- substituted 2-(5-aryl-4H-1,2,4- triazol-3-yl)ethanamines exhibit properties of a trace amine receptor 1 (TAAR1) agonist and can be used to treat diseases mediated by trace amine receptors TAAR1. Therefore, the present invention relates to a number of substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines, a method for production thereof, a pharmaceutical composition on their basis and a use of said compounds.
- TAAR1 trace amine receptor 1
- the present invention provides a compound of formula 1, 1 or a pharmaceutically acceptable salt thereof, where R is: ⁇ 6 - ⁇ 14 aryl optionally substituted with 1-2 substituents selected from the group consisting of: ⁇ 1 - ⁇ 10 alkyl optionally substituted with 1-3 halogen atoms, ⁇ 1 - ⁇ 10 alkoxy optionally substituted with 1-3 halogen atoms or ⁇ 6 - ⁇ 14 aryl optionally substituted with a halogen atom, ⁇ 6 - ⁇ 14 aryl optionally substituted with 1-2 substituents selected from the group including halogen and ⁇ 1 - ⁇ 10 alkoxy optionally substituted with 1-3 halogen atoms, halogen, amino group of formula -N(R 1 ) 2 where each R 1 is independently hydrogen or ⁇ 1 - ⁇ 10 alkyl, nitro group, and C 6 -C 14 aryloxy optionally substituted with ⁇ 1 - ⁇ 10 alkyl; or 5-membered heteroary
- the present invention provides a method for producing the compound of formula 1 comprising the following steps: (a) obtaining the compound of formula 5 by a method selected from: contacting the compound of formula 4 with hydrazine hydrate; or heating the compound of formula 11: or the compound of formula 15: to the melting temperature of said compounds; (b) removing the tert-butoxycarbonyl protecting group, to produce the compound of formula 1 where values of R are as defined above.
- the present invention provides a pharmaceutical composition for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1 comprising a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
- the present invention provides use of the compound of formula 1 or pharmaceutical composition described herein for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1.
- the present invention provides a compound described herein for use in treating a disease, disorder or condition mediated by trace amine receptors TAAR1.
- the present invention provides the use of a compound described herein for producing a drug for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1.
- the present invention provides the method for treating a disease, disorder or condition mediated by trace amine receptors TAAR1 in a subject comprising administration of a therapeutically effective amount of the compound of formula 1 or pharmaceutical composition described herein to the subject.
- the present invention also relates to a method for activating the trace amine receptor TAAR1 by contacting said receptor with the compound of formula 1.
- ⁇ 1 - ⁇ 10 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl and tert- butyl.
- cycloalkyl means a monovalent saturated carbocyclic group containing 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, which can be monocyclic or polycyclic.
- Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and etc.
- aryl refers to a cyclic aromatic hydrocarbon without heteroatoms.
- Aryl groups include monocyclic, bicyclic and polycyclic ring systems and contain 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, even more preferably 6 to 10 carbon atoms in the rings moieties of the groups.
- Aryl groups include, but are not limited to, phenyl and naphthyl.
- the term «aryl» means phenyl.
- heteroaryl as used herein refers to mono- or polycyclic aromatic radicals containing 5 or more ring members of which one or more is/are a heteroatom selected from S, O or N, and the remaining ring atoms are carbon atoms.
- the heteroaryl is 5-membered heteroaryl. In some embodiments of the invention, the heteroaryl contains 1 heteroatom selected from S, O or N. Heteroaryl includes, but is not limited to, thiophene, furan, or pyrrole.
- the term «alkoxy» refers to -O-alkyl group where alkyl is as defined above. Examples of -O-alkyl group include, but are not limited to: methoxy, ethoxy, n-propyloxy, isopropyloxy, n- butyloxy, isobutyloxy, tert-butyloxy.
- « ⁇ 1 - ⁇ 10 alkoxy» refers to -O-alkyl where alkyl is ⁇ 1 - ⁇ 10 alkyl.
- the term «aryloxy» refers to -O-aryl group where aryl is as defined above. Examples of - O-aryl group include, but are not limited to: phenyloxy, naphthyloxy.
- « ⁇ 6 - ⁇ 14 aryloxy» refers to -O-aryl where aryl is ⁇ 6 - ⁇ 14 aryl.
- the term «halogen» refers to fluoride, bromide, chloride, and iodide.
- the term «nitro group» refers to –NO 2 group.
- amino group refers to the group of formula -NR1 2 where each R1, independently of each other, is hydrogen, alkyl or cycloalkyl, e.g., -NH 2 , methylamino, dimethylamino, diethylamino, cyclohexylamino, tert-butylamino or ethylamino.
- optionally substituted group refers to a substituted or unsubstituted group and means that said group may be substituted at one or more positions with 1, 2, 3, 4 or 5 substituents.
- the terms «optionally substituted» and «substituted or unsubstituted» may be used interchangeably.
- substituting groups include, but are not limited to, alkyl, cycloalkyl, halogen, alkoxy group, aryl, nitro group, amino group.
- substituting groups include, but are not limited to, alkyl, cycloalkyl, halogen, alkoxy group, aryl, nitro group, amino group.
- the term «pharmaceutically acceptable» refers to an excipient, it is understood that the excipient meets the required standards of toxicological and manufacturing tests.
- the term «subject» refers to an animal, such as a mammal (including human), that was or will be the subject of treatment, observation or experiment. «Subject» and «patient» may be used interchangeably unless indicated otherwise.
- the methods described in this specification can be used in the treatment of human and/or in veterinary.
- the subject is a mammal.
- the subject is human.
- the terms «therapeutically effective amount» and «effective amount» are used interchangeably and refer to the amount of a compound that is sufficient to conduct the treatment, as defined below, when administered to a patient (e.g., human) in need of such treatment, in one or more doses.
- the therapeutically effective amount may vary depending on the disease to be treated, patient’s weight and/or age, disease severity or route of administration determined by the qualified physician prescribing a preparation or giving care.
- treatment means administration of a compound described herein for the purpose of: (i) delaying disease onset, i.e. preventing the development or delaying clinical symptoms of a disease; (ii) inhibiting a disease, i.e.
- excipient means pharmaceutically acceptable and pharmacologically compatible fillers, solvents, diluents, carriers, disintegrants, glidants, dispersants, preservatives, stabilizers, humectants, emulsifiers, suspending agents, thickeners, sweeteners, odorants, flavoring agents, antibacterial agents, lubricants, regulators of prolonged delivery, etc., the choice and ratio of which depend on the nature and method of prescription and dosage.
- suspending agents examples include ethoxylated isostearyl alcohol, polyoxyethylene, sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, as well as mixtures of these substances.
- the protection against the action of microorganisms can be provided using a variety of antibacterial and antifungal agents such as parabens, chlorobutanol, sorbic acid and similar compounds.
- the composition can also include isotonic agents such as sugars, sodium chloride and the like. Prolonged action of the composition can be provided by agents slowing down active ingredient absorption, e.g., aluminum monostearate and gelatin.
- suitable carriers, solvents, diluents and delivery vehicles include water, ethanol, polyalcohols and mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate).
- suitable carriers include water, ethanol, polyalcohols and mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate).
- fillers include lactose, milk sugar, sodium citrate, calcium carbonate, calcium phosphate and the like.
- disintegrants and dispersants include starch, alginic acid and its salts, silicates.
- lubricants and glidants include magnesium stearate, sodium lauryl sulfate, talc and high molecular weight polyethylene glycol.
- the pharmaceutical composition of the present invention may be formulated as an oral dosage form such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions, sublingual and buccal dosage form, aerosols, implants, dosage form for topical, transdermal, subcutaneous, intramuscular, intravenous, intranasal, intraocular or rectal administration.
- oral dosage form such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions
- sublingual and buccal dosage form such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions
- sublingual and buccal dosage form such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions
- sublingual and buccal dosage form such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions
- aerosols implants
- Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, and the like. Tablets may contain colorants, flavoring agents, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like in addition to an active ingredient.
- Liquid dosage forms suitable for oral administration are emulsions, syrups, elixirs and aqueous suspensions. They include solid dosage forms which are intended to be converted to liquid preparations immediately prior to use.
- Emulsions can be prepared in solutions, e.g., aqueous solutions of propylene glycol, or may contain emulsifiers such as lecithin, sorbitol monooleate or acacia gum.
- Aqueous suspensions can be prepared by dispersing a finely grinded active ingredient in water with viscous materials such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well known suspending agents.
- pharmaceutically acceptable salt means relatively non-toxic organic and inorganic salts of the compounds claimed in the present invention. These salts can be obtained in situ during the synthesis, isolation or purification of compounds, or specially prepared.
- base salts can be specially prepared from the purified free base of the claimed compound and a suitable organic or inorganic acid.
- suitable organic or inorganic acid examples include hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valerates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates, maleates, fumarates, succinates, tartrates, mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like (a detailed description of properties of such salts is provided in Berge S.M., et al., Pharmaceutical Salts, J.
- the present invention relates to substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines exhibiting properties of a trace amine receptor TAAR1 agonist, i.e.
- R is: ⁇ 6 - ⁇ 14 aryl optionally substituted with 1-2 substituents selected from the group consisting of: ⁇ 1 - ⁇ 10 alkyl optionally substituted with 1-3 halogen atoms, ⁇ 1 - ⁇ 10 alkoxy optionally substituted with 1-3 halogen atoms or ⁇ 6 - ⁇ 14 aryl optionally substituted with a halogen atom, ⁇ 6 - ⁇ 14 aryl optionally substituted with 1-2 substituents selected from the group including halogen and ⁇ 1 - ⁇ 10 alkoxy optionally substituted with 1-3 halogen atoms, halogen, amino group of formula -N(R 1 ) 2 where each R 1 is independently hydrogen or ⁇ 1 - ⁇ 10 alkyl, nitro group, and C 6 -C 14 aryloxy optionally substituted with ⁇ 1 - ⁇ 10 alkyl; or 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen
- R is ⁇ 6 - ⁇ 14 aryl, preferably ⁇ 6 - ⁇ 10 aryl, more preferably phenyl.
- R is ⁇ 6 - ⁇ 14 aryl substituted with 1-2 substituents selected from optionally substituted ⁇ 1 - ⁇ 10 alkoxy.
- unsubstituted ⁇ 1 - ⁇ 10 alkoxy is methoxy, ethoxy, propoxy or butoxy.
- substituted ⁇ 1 - ⁇ 10 alkoxy is trifluoromethoxy.
- substituted ⁇ 1 - ⁇ 10 alkoxy is methoxy substituted with ⁇ 6 - ⁇ 14 aryl optionally substituted with a halogen atom.
- R is ⁇ 6 - ⁇ 14 aryl substituted with 1-2 substituents selected from optionally substituted C 6 -C 14 aryloxy.
- ⁇ 6 - ⁇ 14 aryloxy is phenyloxy optionally substituted with ⁇ 1 - ⁇ 10 alkyl, preferably ⁇ 1 - ⁇ 4 alkyl.
- R is ⁇ 6 - ⁇ 14 aryl substituted with 1-2 substituents selected from optionally substituted ⁇ 6 - ⁇ 14 aryl.
- R is phenyl substituted with phenyl optionally substituted with 1-2 substituents selected from halogen or optionally substituted ⁇ 1 - ⁇ 10 alkoxy.
- unsubstituted ⁇ 1 - ⁇ 10 alkoxy is methoxy, ethoxy, propoxy or butoxy.
- substituted ⁇ 1 - ⁇ 10 alkoxy is trifluoromethoxy.
- R is ⁇ 6 - ⁇ 14 aryl substituted with 1-2 substituents selected from optionally substituted ⁇ 1 - ⁇ 10 alkyl, preferably ⁇ 1 - ⁇ 4 alkyl.
- ⁇ 1 - ⁇ 10 alkyl is methyl, ethyl, propyl, butyl. In another embodiment on the invention, substituted ⁇ 1 - ⁇ 10 alkyl is trifluoromethyl.
- R is ⁇ 6 - ⁇ 14 aryl substituted with 1-2 substituents selected from fluoride, chloride or bromide.
- R is ⁇ 6 - ⁇ 14 aryl substituted with an amino group. In a preferred embodiment of the invention, the amino group is selected from methylamino, dimethylamino or diethylamino. In another embodiment of the invention, R is ⁇ 6 - ⁇ 14 aryl substituted with a nitro group.
- R is 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen or sulfur.
- the heteroaryl is thiophene.
- the pharmaceutically acceptable salt is hydrochloride of the compound of formula 1.
- the present invention provides a pharmaceutical composition for treating a disease, disorder or condition mediated by trace amine receptors TAAR1 comprising a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
- the compound of formula 1 or a pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.1 mg to about 1000 mg, preferably about 1 mg to about 800 mg, more preferably about 10 mg to about 600 mg.
- the compound of formula 1 or a pharmaceutically acceptable salt thereof is present in the composition in an amount of 0.1 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg or 1000 mg.
- the excipient may be selected from the group including a pharmaceutically acceptable carrier, diluent, filler and solvent.
- the amount of any individual excipient in the composition may vary depending on the role of excipient, requirements to the dosage of active agent components, and particular demands of the composition. However, the excipient is typically present in the composition in an amount of about 1 wt.% to about 99 wt.%, preferably about 5 wt.% to about 98 wt.%, more preferably about 15 wt.% to about 95 wt.% of the total weight of the composition. In general, the amount of excipient present in the inventive composition is selected from the following: at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or even 95% by weight.
- the pharmaceutical composition of the present invention may be made as dosage forms selected from the group including tablets, powders, granules, pills, suspension, pellets, capsules, sachets and injectable solution.
- the present invention provides the use of the compound of formula 1 or a pharmaceutically acceptable salt thereof or pharmaceutical composition described herein for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1.
- the present invention provides a compound of formula 1, or a pharmaceutically acceptable salt thereof for use in the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1.
- the present invention provides use of the compound of formula 1 or a pharmaceutically acceptable salt thereof or pharmaceutical composition described herein for producing a drug for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1.
- the present invention provides a method for treating disease, disorder or condition mediated by trace amine receptors TAAR1 in a subject comprising administration of a therapeutically effective amount of the compound of formula 1 or pharmaceutical composition described herein to the subject.
- the therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof is about 0.1 mg/day to about 1000 mg/day, preferably about 1 mg/day to about 800 mg/day, more preferably about 10 mg/day to about 600 mg/day administered either as a single dose or as multiple doses.
- multiple doses include two, three or four doses per day.
- the dosage may be altered depending on patient’s age, body weight, susceptibility, symptom or compound efficacy.
- said disease, disorder or condition mediated by trace amine receptors TAAR1 is selected from the group including a mental disorder, cognitive disorder, metabolic disorder, neurological and neurodegenerative disease.
- said disease, disorder or condition mediated by trace amine receptors TAAR1 is selected from the group including depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-induced disorder, psychosis, schizophrenia, obsessive-compulsive disorder, Parkinson’s disease, Alzheimer’s disease, epilepsy, migraine, high blood pressure, alcohol or drug abuse, nicotine addiction, eating disorder, diabetes, diabetes complications, obesity, dyslipidemia, disorders associated with energy consumption and expenditure, disorders associated with impaired body temperature homeostasis, sleep and circadian rhythm disorder, as well as cardiovascular disorder.
- the present invention provides a method for activating the trace amine receptor TAAR1 by contacting said receptor with the compounds of formula 1.
- the present invention provides a method for preparing the compound of general formula 1 or a pharmaceutically acceptable salt thereof comprising the following steps: (a) obtaining the compound of formula 5 by a method selected from: contacting the compound of formula 4 with hydrazine hydrate; or heating the compound of formula 11: or the compounds of formula 15: to the melting temperature of said compounds; (b) removing the tert-butoxycarbonyl protecting group, to obtain the compound of formula 1 where the values of R are as described in claim 1.
- the method described above additionally comprises after step (a) the step of attaching the tetrahydropyranyl protecting group to the cyclic secondary nitrogen atom of the compound of formula 5, where R is phenyl substituted with halogen, followed by the Suzuki reaction, wherein step (b) further includes removing the tetrahydropyranyl protecting group.
- step (b) further includes removing the tetrahydropyranyl protecting group.
- N-acylated imino ether 4 is obtained by reacting poorly stable anhydride 2 with imino ether hydrochloride in alkaline medium; its treatment with hydrazine hydrate yields triazole 5. Removing the Boc-protection yields the desired compound 1.1.
- Method B Synthesis of 1,2,4-triazole derivatives from amidrazones.
- Keto ester 9 is obtained by reacting N-Boc-protected 3-aminopropanoic acid (6) with N- methylmorpholine (7) and isobutyl chloroformate (8) in inert atmosphere. Its interaction with amidrazones (10) yields compounds 11 which spontaneously cyclized to triazoles 5 when heated to their melting temperature. Deprotection of amino group is conducted in the final stage.
- Method C Synthesis of triazole derivatives from imino ethers and 3-tert-butyl-(3- aminopropanehydrazide)carbamate. Compounds 11 are obtained in one step by reacting imino ether 3 with protected 3- aminopropanoic acid hydrazide 12.
- Method D Synthesis of 1,2,4-triazoles from amidine and hydrazides. Compound 15 is obtained by reacting hydrazides 14 with amidine trifluoroacetate 13 in the presence of sodium methylate. The subsequent steps are carried out similarly to the method B.
- Method E Synthesis of 1,2,4-triazole derivatives by the Suzuki reaction. In the first stage, the tetrahydropyranyl protection is attached to the cyclic secondary nitrogen atom. Next, protected compounds 17 are introduced into the Suzuki reaction, and the treatment of biaryl-substituted triazoles 18 by hydrochloric acid in dioxane led to the simultaneous removal of both protective groups.
- Example 1 General procedure for obtaining the compounds of general formula 1. The procedure for obtaining the compounds of general formula 1 is shown in the diagrams above.
- Step 2 The flask was purged with argon and added compound (6), tetrahydrofuran and 1.1 eq. of N-methylmorpholine.
- the reaction mixture was cooled to -30°C and 1 eq. of isobutyl chloroformate was slowly added dropwise. Cooling was stopped 10 minutes after dropwise addition. When the temperature reached 0°C, the precipitate was quickly filtered off. 1 eq. of amidrazone was immediately added to the stock solution and left for 16 hours under stirring. The progress of the reaction was monitored by TLC (1% MeOH/CHCl 3 ). Next, the precipitate was filtered off.
- reaction mixture was evaporated on a rotary evaporator and melted at a temperature of 180-200 °C in an oil bath with a reflux condenser. Purification was carried out using normal phase column chromatography on silica gel in the system ethyl acetate:light petroleum 1:1. The Boc-protecting group was removed with hydrochloric acid in dioxane.
- Step 2 The flask was purged with argon, and 1 eq. of compound (17) in argon flow was dissolved in 30 ml of dioxane followed by addition of 3.5 ml of 20% sodium carbonate solution in distilled water and 2 eq. of boronic acid. In 15 minutes, 0.03 eq. of Pd(PPh 3 ) 4 and 0.03 eq. of PdCl 2 (PPh 3 ) 2 were added.
- Boiling was conducted with a reflux condenser in argon flow for 3-4 hours. The progress of the reaction was monitored by TLC (2% MeOH/CHCl 3 ). Once the reaction has completed, the reaction mixture was extracted with ethyl acetate and successively with water and 5% potassium carbonate solution. The organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. Purification was carried out using normal phase column chromatography on silica gel in the system ethyl acetate:light petroleum 1:1. THP- and Boc-protections were removed from the purified product with hydrochloric acid in dioxane. Example 2.
- the pchTAAR1 expression vector containing the human TAAR1 receptor gene was obtained for conducting experiments.
- the expression vector pcEPAC was used to explore changes in cAMP concentrations in cells in response to the action of various chemical compounds. It provides constitutive expression of the Rluc-EPAC-YFP fused gene, the product of which is a biosensor for monitoring the activation of G ⁇ s signaling pathway. It is based on cAMP-dependent factor EPAC1 (Exchange protein activated by cAMP 1) which changes its conformation in response to binding of cAMP molecule.
- Donor (Rluc) and acceptor (YFP) molecules are located in close proximity in an inactive form, however, when the biosensor binds to cAMP they move significantly away from each other (Barak et al., 2008). Consequently, a decrease in resonance energy transfer from the donor to the acceptor is observed. This is expressed mathematically as the ratio between acceptor luminescence intensity (535 nm) and donor luminescence intensity (480 nm) or the so-called BRET ratio (BRET ratio). Therefore, upon activation of G ⁇ s signaling pathway, which occurs when the receptor under study is activated by a ligand, a decrease in the BRET ratio will be observed.
- BRET HEK293T cell culture (ATCC#CRL-3216) was grown in DMEM medium (Gibco) containing 4.5 g/L glucose until about 70–90% confluence was reached.
- DMEM medium Gibco
- pchTAAR1 3– 5 ⁇ g
- pcEPAC 3–5 ⁇ g
- Lipofectamine 2000 Invitrogen
- the same amount of «empty» pcDNA3.1(+) vector was used as a negative control instead of the pchTAAR1 vector to assess non-specific interaction.
- the cells were removed from the dish, suspended in MEM medium without phenol red (Gibco) containing 2% of fetal bovine serum, and transferred to 96-well plate pretreated with 0.0001% poly-D-lysine solution at 100,000-150,000 cells per well. Cells were grown on plates for 24–48 hours. The culture medium was then carefully aspirated, and 70 ⁇ l of PBS buffer containing Ca 2+ and Mg 2+ ions, 10 ⁇ l of 2 mM IBMX solution (Sigma) and 10 ⁇ l of 50 ⁇ M coelenterazine h solution (Promega) were sequentially added to each well. The plate was incubated for 10 min at room temperature.
- ligand solutions diluted from 0.1 nM to 10 ⁇ M were added and incubated for another 5 minutes at room temperature.
- TAAR1 receptor activation by compounds 1.1 – 1.31 Therefore, it can be concluded based on the data obtained that the compounds of formula 1 according to the present invention have excellent agonistic activity on TAAR1 receptor and can be used to treat diseases mediated by trace amine receptors TAAR1 such as mental disorders, cognitive disorders, neurological and neurodegenerative diseases, schizophrenia, depression, bipolar disorder, attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, Parkinson’s disease, dementia (including Alzheimer’s disease), epilepsy, migraine, high blood pressure (hypertension), alcohol or drug abuse, nicotine addiction, obesity, diabetes, metabolic disorder, disorder associated with energy consumption and expenditure, disorder associated with impaired body temperature homeostasis, sleep and circadian rhythm disorder, and cardiovascular disorder.
- ADHD attention deficit hyperactivity disorder
- Parkinson’s disease dementia
- epilepsy migraine, high blood pressure (hypertension)
- alcohol or drug abuse nicotine addiction, obesity, diabetes, metabolic disorder, disorder associated with energy consumption and expenditure, disorder associated with impaired body temperature homeostasis, sleep
- Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.
- Mol Pharmacol 60, 1181–1188. 3. Sotnikova, T. D., Zorina, O. I., Ghisi, V., Caron, M. G., & Gainetdinov, R. R. (2008). Trace amine associated receptor 1 and movement control. Parkinsonism Relat Disord 14(Suppl.2), S99–102. 4. Lindemann, L., & Hoener, M. C. (2005).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines of general formula 1 and their pharmaceutically acceptable salts which are modulators of trace amine-associated receptor 1 (TAAR1). The method for producing the compounds of formula 1, pharmaceutical composition on their basis and use of said compounds and pharmaceutical composition for treating a disease, disorder or condition mediated by trace amine receptors TAAR1 such as mental disorders, cognitive disorders, metabolic disorders, neurological and neurodegenerative diseases are provided.
Description
SUBSTITUTED 2-(5-ARYL-4H-1,2,4-TRIAZOL-3-YL)ETHANAMINES AS MODULATORS OF TRACE AMINE-ASSOCIATED RECEPTOR 1 (TAAR1) Field of invention The present invention relates to substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines or pharmaceutically acceptable salts thereof exhibiting properties of a trace amine receptor (TAAR1) agonist, a method for production thereof, a pharmaceutical composition on their basis and a use thereof. Background The discovery in 2001 of a new class of monoaminergic receptors coupled to G-proteins (G protein-coupled receptors, GPCRs) – receptors associated with trace amines (Trace Amine- Associated receptors, TAARs, 9 genes identified in humans, TAAR1-TAAR9) – has opened an avenue for understanding the functional role of endogenous trace amines (Trace amines, TA) in mammalian physiology and pathology [Borowsky et al. 2001; Bunzow et al., 2001; Berry et al., 2017]. Trace amines such as β-phenylethylamine (PEA), tyramine, tryptamine and octopamine are structurally similar to classical monoamines and play an important role in invertebrate physiology, but their functions in the body of mammals, where they are present in trace amounts, remain unknown. Determining the role of these amines and their receptors in mammalian physiology would explain many enigmas in pathology and pharmacology of monoaminergic synaptic transmission [Sotnikova et al., 2008]. In general, TAs are present in the CNS and function in parallel with monoaminergic pathways. TAs are structurally related, co- localized and recovered with biogenic amines and neurotransmitters. TAs are thought to posses the neuromodulatory functions of classical neurotransmitters such as dopamine, serotonin and norepinephrine which levels are affected by all antidepressants and antipsychotics currently being used in clinical practice. Dysfunctions in TA physiology have long been associated with schizophrenia and mood disorders. Increased urine PEA levels, changes in tryptamine and tyramine metabolism, and changes in enzymes involved in the synthesis and catabolic pathways of these amines have been shown to be associated with schizophrenia. Four decades ago, PEA hypothesis was developed to explain causes underlining depression development which postulates that PEA deficiency is related to endogenous depression: pilot studies have shown that the use of this amine or its precursor reduces symptoms of depression. Altered levels of trace amines have also been found in patients suffering from attention deficit hyperactivity disorder (ADHD), Parkinson’s disease, and some other brain diseases [Lindemann & Hoener, 2005]. Therefore, it is believed that the identification of new ligands for TA receptors could lead to the development of therapeutics targeting this new neuromodulatory system. TAAR1 is the most investigated receptor among TAARs which represents a new target
for pharmacology of a wide range of mental, neurological and metabolic disorders, and substances acting on TAAR1 are already on the stage of clinical trials [Revel et al. 2011; Revel et al.2012; Berry et al., 2017]. TAAR1 is a proven target for endogenous TAs. The TAAR1 gene is expressed in brain structures associated with mental disorders, in particular in those key areas where modulation of dopamine (ventral tegmental region) and serotonin (brainstem raphe nucleus) occurs, as well as in the amygdala, hypothalamus, nucleus accumbens, entorhinal and frontal cortex and subiculum. Therefore, even if the TA function is not impaired, neuromodulatory effects on monoaminergic pathways could predictably lead to improved mental health. Several TAAR1 agonist molecules and the TAAR1-knockout mouse strain (TAAR1-KO mice) have recently been developed [CA2856204; WO2016016292A1; WO2008052907A1; WO2008046757A1]. Their use in studies has shown that TAAR1 agonists should be effective in the treatment of mental and a number of other disorders such as schizophrenia, depression, ADHD, drug abuse, Parkinson’s disease, sleep disorders by acting either directly or indirectly on monoaminergic pathways [Revel et al.2011; Revel et al.2012]. High TAAR1 expression levels were also found in the pancreas, stomach and intestines, and preclinical studies have shown the efficacy of TAAR1 agonists in metabolic disorders such as obesity and diabetes. TAAR1 expression was also shown in leukocytes suggesting the involvement of this receptor in immunological processes [Lam et al., 2015]. Searches for new TAAR1 receptor modulators and their use as agents for the treatment of mental disorders, cognitive disorders, metabolic disorders, neurological and neurodegenerative diseases are very relevant. Summary of invention The present inventors have surprisingly found that substituted 2-(5-aryl-4H-1,2,4- triazol-3-yl)ethanamines exhibit properties of a trace amine receptor 1 (TAAR1) agonist and can be used to treat diseases mediated by trace amine receptors TAAR1. Therefore, the present invention relates to a number of substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines, a method for production thereof, a pharmaceutical composition on their basis and a use of said compounds. According to one aspect, the present invention provides a compound of formula 1,
1 or a pharmaceutically acceptable salt thereof, where R is: С6-С14 aryl optionally substituted with 1-2 substituents selected from the group
consisting of: С1-С10 alkyl optionally substituted with 1-3 halogen atoms, С1-С10 alkoxy optionally substituted with 1-3 halogen atoms or С6-С14 aryl optionally substituted with a halogen atom, С6-С14 aryl optionally substituted with 1-2 substituents selected from the group including halogen and С1-С10 alkoxy optionally substituted with 1-3 halogen atoms, halogen, amino group of formula -N(R1)2 where each R1 is independently hydrogen or С1-С10 alkyl, nitro group, and C6-C14 aryloxy optionally substituted with С1-С10 alkyl; or 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen or sulfur. According to another aspect, the present invention provides a method for producing the compound of formula 1 comprising the following steps: (a) obtaining the compound of formula 5
by a method selected from: contacting the compound of formula 4
with hydrazine hydrate; or heating the compound of formula 11:
or the compound of formula 15:
to the melting temperature of said compounds; (b) removing the tert-butoxycarbonyl protecting group, to produce the compound of formula 1 where values of R are as defined above. In another aspect, the present invention provides a pharmaceutical composition for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1 comprising a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. According to another aspect, the present invention provides use of the compound of formula 1 or pharmaceutical composition described herein for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1. In another aspect, the present invention provides a compound described herein for use in treating a disease, disorder or condition mediated by trace amine receptors TAAR1. In another aspect, the present invention provides the use of a compound described herein for producing a drug for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1. In another aspect, the present invention provides the method for treating a disease, disorder or condition mediated by trace amine receptors TAAR1 in a subject comprising administration of a therapeutically effective amount of the compound of formula 1 or pharmaceutical composition described herein to the subject. The present invention also relates to a method for activating the trace amine receptor TAAR1 by contacting said receptor with the compound of formula 1. Detailed description of invention Definitions of various terms used to describe the present invention are set forth below. These definitions apply to terms as used in this specification and claims, unless otherwise limited in specific cases, either individually or as part of a larger group. It should be noted that in the present specification and claims the singular forms include references to the plural, unless the context clearly dictates otherwise. The term «alkyl» as used herein refers to straight or branched chain saturated hydrocarbon radicals containing 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms, even more preferably 1 to 4 carbon atoms. Examples of С1-С10 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl and tert- butyl. The term «cycloalkyl» means a monovalent saturated carbocyclic group containing 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, which can be monocyclic or polycyclic. Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, cyclooctyl, and etc. The term «aryl» as used herein refers to a cyclic aromatic hydrocarbon without heteroatoms. Aryl groups include monocyclic, bicyclic and polycyclic ring systems and contain 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, even more preferably 6 to 10 carbon atoms in the rings moieties of the groups. Aryl groups include, but are not limited to, phenyl and naphthyl. Preferably, the term «aryl» means phenyl. The term «heteroaryl» as used herein refers to mono- or polycyclic aromatic radicals containing 5 or more ring members of which one or more is/are a heteroatom selected from S, O or N, and the remaining ring atoms are carbon atoms. In some embodiments of the invention, the heteroaryl is 5-membered heteroaryl. In some embodiments of the invention, the heteroaryl contains 1 heteroatom selected from S, O or N. Heteroaryl includes, but is not limited to, thiophene, furan, or pyrrole. The term «alkoxy» refers to -O-alkyl group where alkyl is as defined above. Examples of -O-alkyl group include, but are not limited to: methoxy, ethoxy, n-propyloxy, isopropyloxy, n- butyloxy, isobutyloxy, tert-butyloxy. «С1-С10 alkoxy» refers to -O-alkyl where alkyl is С1-С10 alkyl. The term «aryloxy» refers to -O-aryl group where aryl is as defined above. Examples of - O-aryl group include, but are not limited to: phenyloxy, naphthyloxy. «С6-С14 aryloxy» refers to -O-aryl where aryl is С6-С14 aryl. The term «halogen» refers to fluoride, bromide, chloride, and iodide. The term «nitro group» refers to –NO2 group. The term «amino group» refers to the group of formula -NR1 2 where each R1, independently of each other, is hydrogen, alkyl or cycloalkyl, e.g., -NH2, methylamino, dimethylamino, diethylamino, cyclohexylamino, tert-butylamino or ethylamino. In this specification, the term «optionally substituted» group refers to a substituted or unsubstituted group and means that said group may be substituted at one or more positions with 1, 2, 3, 4 or 5 substituents. The terms «optionally substituted» and «substituted or unsubstituted» may be used interchangeably. Examples of substituting groups (substituents) include, but are not limited to, alkyl, cycloalkyl, halogen, alkoxy group, aryl, nitro group, amino group. Those skilled in the art will appreciate that compounds of the present invention may exhibit properties of tautomerism, conformational isomerism, geometric isomerism and/or optical isomerism. Since the depicted structural formulas in the specification and claims may represent only one of the possible tautomeric, conformational isomeric, optical isomeric or geometric isomeric forms, it should be understood that the present invention encompasses any tautomeric, conformational isomeric, optical isomeric and/or geometric isomeric forms of
compounds having one or more uses described herein, as well as mixtures of these different forms. By «pharmaceutically acceptable» is meant a material that is not biologically or otherwise undesirable, for example, this material can be incorporated in a pharmaceutical composition administered to a subject without causing any undesirable biological effects or harmful interaction with any of other components of the composition containing the same. When the term «pharmaceutically acceptable» is used to refer to an excipient, it is understood that the excipient meets the required standards of toxicological and manufacturing tests. The term «subject» refers to an animal, such as a mammal (including human), that was or will be the subject of treatment, observation or experiment. «Subject» and «patient» may be used interchangeably unless indicated otherwise. The methods described in this specification can be used in the treatment of human and/or in veterinary. In some embodiments, the subject is a mammal. In some embodiments, the subject is human. The terms «therapeutically effective amount» and «effective amount» are used interchangeably and refer to the amount of a compound that is sufficient to conduct the treatment, as defined below, when administered to a patient (e.g., human) in need of such treatment, in one or more doses. The therapeutically effective amount may vary depending on the disease to be treated, patient’s weight and/or age, disease severity or route of administration determined by the qualified physician prescribing a preparation or giving care. The term «treatment» means administration of a compound described herein for the purpose of: (i) delaying disease onset, i.e. preventing the development or delaying clinical symptoms of a disease; (ii) inhibiting a disease, i.e. arresting the development of clinical symptoms; and/or (iii) alleviating a disease, i.e. causing regression of clinical symptoms or their severity. The term «excipient» means pharmaceutically acceptable and pharmacologically compatible fillers, solvents, diluents, carriers, disintegrants, glidants, dispersants, preservatives, stabilizers, humectants, emulsifiers, suspending agents, thickeners, sweeteners, odorants, flavoring agents, antibacterial agents, lubricants, regulators of prolonged delivery, etc., the choice and ratio of which depend on the nature and method of prescription and dosage. Examples of suspending agents include ethoxylated isostearyl alcohol, polyoxyethylene, sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, as well as mixtures of these substances. The protection against the action of microorganisms can be provided using a variety of antibacterial and antifungal agents such as parabens, chlorobutanol, sorbic acid and similar compounds. The composition can also include isotonic agents such as sugars, sodium chloride and the like. Prolonged action of the composition can be provided by agents slowing down active ingredient absorption, e.g., aluminum
monostearate and gelatin. Examples of suitable carriers, solvents, diluents and delivery vehicles include water, ethanol, polyalcohols and mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate). Examples of fillers include lactose, milk sugar, sodium citrate, calcium carbonate, calcium phosphate and the like. Examples of disintegrants and dispersants include starch, alginic acid and its salts, silicates. Examples of lubricants and glidants include magnesium stearate, sodium lauryl sulfate, talc and high molecular weight polyethylene glycol. The pharmaceutical composition of the present invention may be formulated as an oral dosage form such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions or suspensions, sublingual and buccal dosage form, aerosols, implants, dosage form for topical, transdermal, subcutaneous, intramuscular, intravenous, intranasal, intraocular or rectal administration. The most convenient route of administration is commonly oral using a normal daily dosage regimen which can be adjusted depending on disease severity and patient’s response. In a tableting process, an active ingredient is usually mixed with a carrier having the necessary binding capacity in suitable proportions and compressed into the desired shape and size. Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, and the like. Tablets may contain colorants, flavoring agents, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like in addition to an active ingredient. Liquid dosage forms suitable for oral administration are emulsions, syrups, elixirs and aqueous suspensions. They include solid dosage forms which are intended to be converted to liquid preparations immediately prior to use. Emulsions can be prepared in solutions, e.g., aqueous solutions of propylene glycol, or may contain emulsifiers such as lecithin, sorbitol monooleate or acacia gum. Aqueous suspensions can be prepared by dispersing a finely grinded active ingredient in water with viscous materials such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well known suspending agents. The term «pharmaceutically acceptable salt» means relatively non-toxic organic and inorganic salts of the compounds claimed in the present invention. These salts can be obtained in situ during the synthesis, isolation or purification of compounds, or specially prepared. In particular, base salts can be specially prepared from the purified free base of the claimed compound and a suitable organic or inorganic acid. Examples of salts obtained in this manner are hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valerates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates,
maleates, fumarates, succinates, tartrates, mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like (a detailed description of properties of such salts is provided in Berge S.M., et al., Pharmaceutical Salts, J. Pharm. Sci. 1977, 66: 1- 19). The present invention relates to substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines exhibiting properties of a trace amine receptor TAAR1 agonist, i.e. compounds of general formula 1:
or pharmaceutically acceptable salts thereof, where R is: С6-С14 aryl optionally substituted with 1-2 substituents selected from the group consisting of: С1-С10 alkyl optionally substituted with 1-3 halogen atoms, С1-С10 alkoxy optionally substituted with 1-3 halogen atoms or С6-С14 aryl optionally substituted with a halogen atom, С6-С14 aryl optionally substituted with 1-2 substituents selected from the group including halogen and С1-С10 alkoxy optionally substituted with 1-3 halogen atoms, halogen, amino group of formula -N(R1)2 where each R1 is independently hydrogen or С1-С10 alkyl, nitro group, and C6-C14 aryloxy optionally substituted with С1-С10 alkyl; or 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen or sulfur. In one embodiment of the invention, R is С6-С14 aryl, preferably С6-С10 aryl, more preferably phenyl. In another embodiment of the invention, R is С6-С14 aryl substituted with 1-2 substituents selected from optionally substituted С1-С10 alkoxy. In a preferred embodiment of the invention, unsubstituted С1-С10 alkoxy is methoxy, ethoxy, propoxy or butoxy. In another embodiment of the invention, substituted С1-С10 alkoxy is trifluoromethoxy. In another embodiment of the invention, substituted С1-С10 alkoxy is methoxy substituted with С6-С14 aryl optionally
substituted with a halogen atom. In another embodiment of the invention, R is С6-С14 aryl substituted with 1-2 substituents selected from optionally substituted C6-C14 aryloxy. In a preferred embodiment of the invention, С6-С14 aryloxy is phenyloxy optionally substituted with С1-С10 alkyl, preferably С1-С4 alkyl. In another embodiment of the invention, R is С6-С14 aryl substituted with 1-2 substituents selected from optionally substituted С6-С14 aryl. In a preferred embodiment of the invention, R is phenyl substituted with phenyl optionally substituted with 1-2 substituents selected from halogen or optionally substituted С1-С10 alkoxy. In a preferred embodiment of the invention, unsubstituted С1-С10 alkoxy is methoxy, ethoxy, propoxy or butoxy. In another preferred embodiment of the invention, substituted С1-С10 alkoxy is trifluoromethoxy. In another embodiment of the invention, R is С6-С14 aryl substituted with 1-2 substituents selected from optionally substituted С1-С10 alkyl, preferably С1-С4 alkyl. In a preferred embodiment of the invention, С1-С10 alkyl is methyl, ethyl, propyl, butyl. In another embodiment on the invention, substituted С1-С10 alkyl is trifluoromethyl. In another embodiment of the invention, R is С6-С14 aryl substituted with 1-2 substituents selected from fluoride, chloride or bromide. In another embodiment of the invention, R is С6-С14 aryl substituted with an amino group. In a preferred embodiment of the invention, the amino group is selected from methylamino, dimethylamino or diethylamino. In another embodiment of the invention, R is С6-С14 aryl substituted with a nitro group. In another embodiment of the invention, R is 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen or sulfur. In a preferred embodiment of the invention, the heteroaryl is thiophene. In a preferred embodiment, the pharmaceutically acceptable salt is hydrochloride of the compound of formula 1. The following compounds are preferred: 5-(3-methoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.1, TRX-0037); 5-(3-trifluoromethylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.2, TRX-0038); 5-(4-trifluoromethoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.3, TRX-0039); 5-(2-thiophene)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.4, TRX-0040); 5-(4-(benzyloxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.5, TRX-0041); 5-(3-bromophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.6, TRX-0042); 5-(3,5-dichlorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.7, TRX-0043); 5-(phenyl-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.8, TRX-0044); 5-(2-methylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.9, TRX-0045);
5-(4-ethoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.10, TRX-0046); 5-(4-chlorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.11, TRX-0047); 5-(2-bromophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.12, TRX-0048); 5-(4-(dimethylamino)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.13, TRX-0049); 5-(3,5-dimethylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.14, TRX-0050); 5-(4-fluorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.15, TRX-0051); 5-(3-nitrophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.16, TRX-0052); 5-(4-butoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.17, TRX-0053); 5-(4-((2-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.18, TRX- 0054); 5-(4-((3-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.19, TRX- 0055); 5-(4-((4-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.20, TRX- 0056); 5-(3-methyl-4-((3-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.21, TRX-0057); 5-(3-methyl-4-((4-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.22, TRX-0058); 5-(4-(4-methoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.23, TRX- 0059); 5-(4-(4-trifluoromethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.24, TRX-0060); 5-(4-(3-fluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.25, TRX-0061); 5-(4-(2,4-difluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.26, TRX- 0062); 5-(4-(4-chlorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.27, TRX-0063); 5-(4-(3,4-dimethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.28, TRX- 0064); 5-(4-(3,5-difluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.29, TRX- 0065); 5-(3-(4-trifluoromethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.30, TRX-0066); 5-(4-(4-methylphenoxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.31, TRX- 0067). In another aspect, the present invention provides a pharmaceutical composition for
treating a disease, disorder or condition mediated by trace amine receptors TAAR1 comprising a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. In some embodiments, the compound of formula 1 or a pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.1 mg to about 1000 mg, preferably about 1 mg to about 800 mg, more preferably about 10 mg to about 600 mg. In some embodiments, the compound of formula 1 or a pharmaceutically acceptable salt thereof is present in the composition in an amount of 0.1 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg or 1000 mg. In some embodiments, the excipient may be selected from the group including a pharmaceutically acceptable carrier, diluent, filler and solvent. The amount of any individual excipient in the composition may vary depending on the role of excipient, requirements to the dosage of active agent components, and particular demands of the composition. However, the excipient is typically present in the composition in an amount of about 1 wt.% to about 99 wt.%, preferably about 5 wt.% to about 98 wt.%, more preferably about 15 wt.% to about 95 wt.% of the total weight of the composition. In general, the amount of excipient present in the inventive composition is selected from the following: at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or even 95% by weight. The pharmaceutical composition of the present invention may be made as dosage forms selected from the group including tablets, powders, granules, pills, suspension, pellets, capsules, sachets and injectable solution. In another aspect, the present invention provides the use of the compound of formula 1 or a pharmaceutically acceptable salt thereof or pharmaceutical composition described herein for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1. According to another aspect, the present invention provides a compound of formula 1, or a pharmaceutically acceptable salt thereof for use in the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1. In another aspect, the present invention provides use of the compound of formula 1 or a pharmaceutically acceptable salt thereof or pharmaceutical composition described herein for producing a drug for the treatment of disease, disorder or condition mediated by trace amine receptors TAAR1.
In another aspect, the present invention provides a method for treating disease, disorder or condition mediated by trace amine receptors TAAR1 in a subject comprising administration of a therapeutically effective amount of the compound of formula 1 or pharmaceutical composition described herein to the subject. Typically, the therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof is about 0.1 mg/day to about 1000 mg/day, preferably about 1 mg/day to about 800 mg/day, more preferably about 10 mg/day to about 600 mg/day administered either as a single dose or as multiple doses. In some embodiments, multiple doses include two, three or four doses per day. The dosage may be altered depending on patient’s age, body weight, susceptibility, symptom or compound efficacy. In some embodiments of the invention, said disease, disorder or condition mediated by trace amine receptors TAAR1 is selected from the group including a mental disorder, cognitive disorder, metabolic disorder, neurological and neurodegenerative disease. In some embodiments of the invention, said disease, disorder or condition mediated by trace amine receptors TAAR1 is selected from the group including depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-induced disorder, psychosis, schizophrenia, obsessive-compulsive disorder, Parkinson’s disease, Alzheimer’s disease, epilepsy, migraine, high blood pressure, alcohol or drug abuse, nicotine addiction, eating disorder, diabetes, diabetes complications, obesity, dyslipidemia, disorders associated with energy consumption and expenditure, disorders associated with impaired body temperature homeostasis, sleep and circadian rhythm disorder, as well as cardiovascular disorder. In another aspect, the present invention provides a method for activating the trace amine receptor TAAR1 by contacting said receptor with the compounds of formula 1. In another aspect, the present invention provides a method for preparing the compound of general formula 1 or a pharmaceutically acceptable salt thereof comprising the following steps: (a) obtaining the compound of formula 5
by a method selected from: contacting the compound of formula 4
with hydrazine hydrate; or
heating the compound of formula 11:
or the compounds of formula 15:
to the melting temperature of said compounds; (b) removing the tert-butoxycarbonyl protecting group, to obtain the compound of formula 1 where the values of R are as described in claim 1. In another embodiment of the invention, the method described above additionally comprises after step (a) the step of attaching the tetrahydropyranyl protecting group to the cyclic secondary nitrogen atom of the compound of formula 5, where R is phenyl substituted with halogen, followed by the Suzuki reaction, wherein step (b) further includes removing the tetrahydropyranyl protecting group. Various synthetic approaches to the production of the compound of formula 1 depending on the nature of substituent R are detailed below. Method A. Synthesis of 1,2,4-triazoles from imino ethers and anhydride (2).
N-acylated imino ether 4 is obtained by reacting poorly stable anhydride 2 with imino ether hydrochloride in alkaline medium; its treatment with hydrazine hydrate yields triazole 5. Removing the Boc-protection yields the desired compound 1.1. Method B. Synthesis of 1,2,4-triazole derivatives from amidrazones.
Keto ester 9 is obtained by reacting N-Boc-protected 3-aminopropanoic acid (6) with N- methylmorpholine (7) and isobutyl chloroformate (8) in inert atmosphere. Its interaction with amidrazones (10) yields compounds 11 which spontaneously cyclized to triazoles 5 when heated to their melting temperature. Deprotection of amino group is conducted in the final stage. Method C. Synthesis of triazole derivatives from imino ethers and 3-tert-butyl-(3- aminopropanehydrazide)carbamate.
Compounds 11 are obtained in one step by reacting imino ether 3 with protected 3- aminopropanoic acid hydrazide 12. Thereafter, synthesis is carried out similarly to the method B. Method D. Synthesis of 1,2,4-triazoles from amidine and hydrazides.
Compound 15 is obtained by reacting hydrazides 14 with amidine trifluoroacetate 13 in the presence of sodium methylate. The subsequent steps are carried out similarly to the method B.
Method E. Synthesis of 1,2,4-triazole derivatives by the Suzuki reaction.
In the first stage, the tetrahydropyranyl protection is attached to the cyclic secondary nitrogen atom. Next, protected compounds 17 are introduced into the Suzuki reaction, and the treatment of biaryl-substituted triazoles 18 by hydrochloric acid in dioxane led to the simultaneous removal of both protective groups. The present invention will now be described in various embodiments which are not intended to limit its scope. On the contrary, the present invention covers all alternatives, modifications and equivalents that may be included within the scope of the claims. Therefore, the following examples, which include particular embodiments of the invention, illustrate but do not limit the present invention. Example 1. General procedure for obtaining the compounds of general formula 1. The procedure for obtaining the compounds of general formula 1 is shown in the diagrams above. Compound 2.30 g of 3-aminopropionic acid (336.7 mmol) was added 14.83 g of sodium hydroxide (370.4 mmol) dissolved in the mixture of water:isopropanol 1:1 (150:150 ml) and 66.13 g of di-tert-butyl dicarbonate (303 mmol) and left for 12 hours under stirring. The progress of the reaction was monitored by TLC. Once the reaction has completed, isopropanol was evaporated. The aqueous layer was extracted 2 times with ethyl acetate, the aqueous phase was acidified with 3% HCl to pH=2, the resulting precipitate was filtered, and the remaining water was extracted with ethyl acetate. The organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. The substance remained on the filter was dried in a desiccator over alkali. The yield was 44.5 g (78%). 30 mmol of 3-(tert-butoxycarbonyl)aminopropionic acid (5.601 g) was dissolved in anhydrous methylene chloride, added 17.5 mmol of dicyclohexylcarbodiimide (DCC) (1.562 g) and left overnight under stirring. The resulting precipitate was filtered, and a stock solution was
used immediately in the next stage. Synthesis of 1,2,4-triazoles according to the method A. 1 eq. of imino ether was suspended in dry methylene chloride, added 3 eq. of triethylamine and allowed to mix well. In 10 minutes, 1 eq. of N,N-di-tert-butoxycarbonyl-3-aminopropionic acid anhydride (2) was added dropwise. The progress of the reaction was monitored by TLC (2% methanol in chloroform), then the reaction mixture was extracted with water, the organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. Methylene chloride was added with the following gentle dropwise addition of 3 eq. of hydrazine hydrate. Once the reaction has completed, the reaction mixture was extracted successively with water, 5% potassium carbonate solution, 3% citric acid solution. The organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. Purification was carried out using normal phase column chromatography on silica gel in the system chloroform:methanol (3:1). The Boc-protecting group was removed with hydrochloric acid in dioxane. Synthesis of 1,2,4-triazoles according to the method B. (Step 1 - synthesis of amidrazones) 1 eq. of imino ether (as free base) was dissolved in tetrahydrofuran and added 1.5 eq. of hydrazine hydrate, left for 48 hours under stirring. The reaction mixture was evaporated on a rotary evaporator and reevaporated with toluene. (Step 2) The flask was purged with argon and added compound (6), tetrahydrofuran and 1.1 eq. of N-methylmorpholine. The reaction mixture was cooled to -30°C and 1 eq. of isobutyl chloroformate was slowly added dropwise. Cooling was stopped 10 minutes after dropwise addition. When the temperature reached 0°C, the precipitate was quickly filtered off. 1 eq. of amidrazone was immediately added to the stock solution and left for 16 hours under stirring. The progress of the reaction was monitored by TLC (1% MeOH/CHCl3). Next, the precipitate was filtered off. For the cyclization of triazole ring, the substance was melted in an oil bath at a temperature of 110–180°C. Purification was carried out using normal phase column chromatography on silica gel in the system chloroform:methanol 5%. Hydrochloric acid in dioxane was used to remove the Boc-protecting group. Synthesis of 1,2,4-triazoles according to the method C. 1 eq. of imino ether was dissolved in 2 eq. of triethylamine and added 1 eq. of 3-tert-butyl-(3- aminopropanehydrazide)carbamate. The reaction was left for 48 hours under stirring. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. For the cyclization of triazole ring the substance was melted in an oil bath at a temperature of 180-200°C. Purification was carried out using normal phase column chromatography in the system chloroform:methanol 2%. The Boc-protecting group was removed by adding hydrochloric acid in dioxane. Synthesis of 1,2,4-triazoles according to the method D.1.2 eq. of compound (13) was
dissolved in a small amount of dry methanol, added 1.2 eq. of freshly prepared sodium methylate and in 15 minutes – 1 eq. of hydrazide. The reaction mass was left for 24-48 hours under stirring. The progress of the reaction was monitored by TLC (2% MeOH/CHCl3). Once the reaction has completed, the reaction mixture was evaporated on a rotary evaporator and melted at a temperature of 180-200 °C in an oil bath with a reflux condenser. Purification was carried out using normal phase column chromatography on silica gel in the system ethyl acetate:light petroleum 1:1. The Boc-protecting group was removed with hydrochloric acid in dioxane. Synthesis of 1,2,4-triazoles according to the method E (Step 1 – creation of tetrahydropyranyl protection) compound (5) (2.06 mmol, 1 eq.) was dissolved in dry tetrahydrofuran, then 3,4-dihydro-2H-pyran (0.93 ml, 10.3 mmol, 5 eq.) and para- toluenesulfonic acid (0.035 g, 0.21 mmol, 0.1 eq.) were added and boiled with a reflux condenser for 5 hours. The progress of the reaction was monitored by TLC (chloroform). Next, sequential extraction was carried out using ethyl acetate with water, 5% potassium carbonate solution, 3% citric acid solution. The organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. The yield is quantitative. (Step 2) The flask was purged with argon, and 1 eq. of compound (17) in argon flow was dissolved in 30 ml of dioxane followed by addition of 3.5 ml of 20% sodium carbonate solution in distilled water and 2 eq. of boronic acid. In 15 minutes, 0.03 eq. of Pd(PPh3)4 and 0.03 eq. of PdCl2(PPh3)2 were added. Boiling was conducted with a reflux condenser in argon flow for 3-4 hours. The progress of the reaction was monitored by TLC (2% MeOH/CHCl3). Once the reaction has completed, the reaction mixture was extracted with ethyl acetate and successively with water and 5% potassium carbonate solution. The organic layer was passed through sodium sulfate and evaporated on a rotary evaporator. Purification was carried out using normal phase column chromatography on silica gel in the system ethyl acetate:light petroleum 1:1. THP- and Boc-protections were removed from the purified product with hydrochloric acid in dioxane. Example 2. Synthesis of 5-(3-methoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.1, TRX-0037). The yield was 0.924 g (48%). Tm=235-236°C. HRMS (ESI) found for С11H14N4O [M+H+] 219.1240 Da, calculated 219.1240 Da. 1H NMR (300 MHz, DMSO) δ 8.27 (br.s, 3H), 7.71-7.66 (m, 2H), 7.44 (t, J = 8.0 Hz, 1H), 7.11 – 7.05 (m, 1H), 3.82 (s, 3H), 3.33-3.24 (m, 2H), 3.22-3.14 (m, 2H). 13C NMR (75 MHz, DMSO) δ 159.6, 156.1, 155.6, 130.2, 128.7, 118.6, 116.3, 111.4, 55.4, 36.8, 24.3. Example 3. Synthesis of 5-(3-trifluoromethylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.2, TRX-0038). The yield was 0.110 g (22%). Tm=242-244 °C. HRMS (ESI) found for С11H11F3N4 [M+H+] 257.1009 Da, calculated 257.1009 Da. 1 H NMR (300 MHz, DMSO) δ 8.35 (br.s, 5H), 7.89 – 7.67 (m, 2H), 3.35 – 3.14 (m, 4H).13C NMR
(75 MHz, DMSO) δ 156.9, 155.6, 130.4, 130.3, 130.0 (q, J = 31.8 Hz), 129.9, 126.2 (q, J = 3.5 Hz), 124.1 (q, J = 272.4 Hz), 122.4 (q, J = 3.8 Hz), 36.8, 24.2. Example 4. Synthesis of 5-(4-trifluoromethoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.3, TRX-0039). The yield was 0.054 g (12%). Tm=253-254°C. HRMS (ESI) found for С11H11F3N4O [M+H+] 273.0958 Da, calculated 273.0958 Da. 1H NMR (300 MHz, DMSO) δ 8.28 (br.s, 3H), 8.20 – 8.14 (m, 2H), 7.53 – 7.47 (m, 2H), 3.30 – 3.21 (m, 2H), 3.20 – 3.12 (m, 2H). 13C NMR (75 MHz, DMSO) δ 157.1, 155.9, 149.1 (q, J = 1.6 Hz), 128.6, 128.1, 121.5, 118.4 (q, J = 256.7 Hz), 36.9, 24.4. Example 5. Synthesis of 5-(2-thiophene)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.4, TRX-0040). The yield was 0.164 g (24%). Tm=248-250 °C. HRMS (ESI) found for С8H10N4S [M+H+] 195.0699 Da, calculated 195.0699 Da. 1H NMR (300 MHz, DMSO) δ 8.17 (br.s, 3H), 7.71 – 7.62 (m, 2H), 7.19 – 7.14 (m, 1H), 3.27 – 3.15 (m, 2H), 3.13 – 3.04 (m, 2H). 13C NMR (75 MHz, DMSO) δ 155.1, 153.3, 130.8, 127.6, 127.3, 126.1, 36.3, 23.7. Example 6. Synthesis of 5-(4-(benzyloxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.5, TRX-0041). The yield was 4.568 g (54%). Tm= 238-240°C. HRMS (ESI) found for С17H18N4O [M+H+] 295.1553 Da, calculated 295.1553 Da. 1H NMR (300 MHz, DMSO) δ 8.24 (br.s, 3H), 8.10 – 8.05 (m, 2H), 7.50 – 7.31 (m, 5H), 7.22 – 7.17 (m, 2H), 5.19 (s, 2H), 3.33 – 3.22 (m, 2H), 3.20 – 3.13 (m, 1H). 13C NMR (75 MHz, DMSO) δ 160.0, 155.3, 155.0, 136.4, 128.2, 128.0, 127.8, 127.7, 118.9, 115.2, 69.3, 36.6, 24.1. Example 7. Synthesis of 5-(3-bromophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.6, TRX-0042). The yield was 4.060 g (45%). Tm=239-241 °C. HRMS (ESI) found for С10H11BrN4 [M+H+]] 269.0240 Da, calculated 269.0240 Da. 1H NMR (300 MHz, DMSO) δ 8.33 (br.s, 3H), 8.24 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.51 – 7.44 (m, 1H), 3.32 – 3.22 (m, 2H), 3.21 – 3.14 (m, 2H). 13C NMR (75 MHz, DMSO) δ 156.4, 155.6, 132.5, 131.2, 131.1, 128.6, 125.1, 122.2, 36.8, 24.2. Example 8. Synthesis of 5-(3,5-dichlorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.7, TRX-0043). The yield was 0.102 g (36%). Tm=222-224°C. HRMS (ESI) found for С10H10Cl2N4 [M+H+] 257.0355 Da, calculated 257.0355 Da. 1H NMR (300 MHz, DMSO) δ 8.31 (br.s, 3H), 8.02 (d, J = 1.8 Hz, 2H), 7.70 – 7.68 (m, 1H), 3.29 – 3.20 (m, 2H), 3.19 – 3.11 (m, 2H).13C NMR (75 MHz, DMSO) δ 156.6, 155.8, 134.7, 133.3, 128.7, 124.3, 36.8, 24.1. Example 9. Synthesis of 5-(phenyl-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.8, TRX-0044). The yield was 0.04 g (8%). Tm=250-252 °C.
HRMS (ESI) found for С10H12N4 [M+H+] 189.1135 Da, calculated 189.1135 Da. 1H NMR (300 MHz, DMSO) δ 8.17 (br.s, 3H), 8.08 – 8.02 (m, 2H), 7.55 – 7.44 (m, 3H), 3.32 – 3.20 (m, 2H), 3.17 – 3.09 (m, 2H).13C NMR (75 MHz, DMSO) δ 156.6, 154.1, 129.9, 129.0, 128.5, 126.1, 37.2, 24.6. Example 10. Synthesis of 5-(2-methylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.9, TRX-0045). The yield was 0.110 g (22%). Tm=244-245°C. HRMS (ESI) found for С11H14N4 [M+H+] 203.1291 Da, calculated 203.1291 Da. 1H NMR (300 MHz, DMSO) δ 8.25 (br.s, 3H), 7.78 (d, J = 7.4 Hz, 1H), 7.43 – 7.29 (m, 3H), 3.33 – 3.22 (m, 2H), 3.21 – 3.14 (m, 2H), 2.53 (s, 3H). 13C NMR (75 MHz, DMSO) δ 157.1, 155.1, 136.6, 131.1, 129.0, 129.2, 127.5, 125.9, 36.8, 30.6, 24.3. Example 11. Synthesis of 5-(4-ethoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.10, TRX-0046). The yield was 0.051 g (44%). Tm=226-228 °C. HRMS (ESI) found for С12H16N4O [M+H+] 233.1397 Da, calculated 233.1397 Da. 1H NMR (300 MHz, DMSO) δ 8.16 (br.s, 3H), 8.01 (d, J = 8.7 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 4.10 (q, J = 6.9 Hz, 2H), 3.31 – 3.19 (m, 2H), 3.17 – 3.08 (m, 2H), 1.34 (t, J = 6.9 Hz, 3H).13C NMR (75 MHz, DMSO) δ 160.3, 156.8, 156.4, 128.1, 120.1, 115.1, 63.6, 37.3, 24.9, 14.8. Example 12. Synthesis of 5-(4-chlorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.11, TRX-0047). The yield was 0.025 g (13%). Tm=239-241°C. HRMS (ESI) found for С10H11ClN4 [M+H+] 223.0745 Da, calculated 223.0745 Da. 1H NMR (300 MHz, DMSO) δ 8.12 (s, 2H), 8.05 – 8.00 (m, 2H), 7.58 – 7.53 (m, 2H), 3.29 – 3.17 (m, 2H), 3.14 – 3.05 (m, 2H). 13C NMR (75 MHz, DMSO) δ 157.7, 156.4, 134.3, 129.2, 128.3, 127.9, 37.2, 24.6. Example 13. Synthesis of 5-(2-bromophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.12, TRX-0048). The yield was 0.044 g (33%). Tm=194-196 °C. HRMS (ESI) found for С10H11BrN4 [M+H+] 267.0240 Da, calculated 267.0240 Da. 1H NMR (300 MHz, DMSO) δ 8.25 (s, 3H), 7.79 – 7.73 (m, 2H), 7.53 – 7.46 (m, 1H), 7.44 – 7.38 (m, 1H), 3.29 – 3.11 (m, 4H). 13C NMR (75 MHz, DMSO) δ 157.4, 155.8, 133.8, 131.9, 131.4, 131.0, 128.0, 121.3, 37.2, 24.6. Example 14. Synthesis of 5-(4-(dimethylamino)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.13, TRX-0049). The yield was 0.017 g (9%). Tm=244.5-246°C. HRMS (ESI) found for С12H17N5 [M+H+] 232.1557 Da, calculated 232.1557 Da. 1H NMR (300 MHz, DMSO) δ 8.20 (s, 3H), 8.02 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.1 Hz, 2H), 3.35 – 3.24 (m, 2H), 3.21 – 3.12 (m, 2H), 3.03 (s, 6H). 13C NMR (75 MHz, DMSO) δ 154.2, 154.1, 151.8, 128.2, 112.3, 36.6, 25.5, 24.1.
Example 15. Synthesis of 5-(3,5-dimethylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.14, TRX-0050). The yield was 0.138 g (41%). Tm=232-234 °C. HRMS (ESI) found for С12H16N4 [M+H+] 217.1448 Da, calculated 217.1448 Da. 1H NMR (300 MHz, DMSO) δ 8.34 (br.s, 3H), 7.76 (s, 2H), 7.17 (s, 1H), 3.37 – 3.16 (m, 4H), 2.33 (s, 6H).13C NMR (75 MHz, DMSO) δ 155.7, 155.2, 138.4, 132.2, 126.5, 124.3, 36.7, 24.2, 21.0. Example 16. Synthesis of 5-(4-fluorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.15, TRX-0051). The yield was 0.028 g (16%). Tm=253-256°C. HRMS (ESI) found for С10H11FN4 [M+H+] 207.1041 Da, calculated 207.1041 Da. 1H NMR (300 MHz, DMSO) δ 8.25 – 8.04 (m, 5H), 7.46 – 7.27 (m, 2H), 3.30 – 3.19 (m, 2H), 3.17 – 3.08 (m, 2H).13C NMR (75 MHz, DMSO) δ 162.93 (d, J = 246.5 Hz), 156.89, 155.93, 128.38 (d, J = 8.7 Hz), 125.56, 115.97 (d, J = 22.0 Hz), 36.94, 24.45. Example 17. Synthesis of 5-(3-nitrophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.16, TRX-0052). The yield was 0.057 g (48%). Tm=214-216 °C. HRMS (ESI) found for С10H11N5O2 [M+H+] 234.0986 Da, calculated 234.0986 Da. 1H NMR (300 MHz, DMSO) δ 8.78 – 8.76 (m, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.28 (dd, J = 8.2, 1.6 Hz, 1H), 8.18 (br.s, 3H), 7.79 (t, J = 8.0 Hz, 1H), 3.32 – 3.20 (m, 2H), 3.19 – 3.11 (m, 2H). 13C NMR (75 MHz, DMSO) δ 157.9, 156.1, 148.5, 132.2, 132.0, 131.0, 124.2, 120.5, 37.2, 24.5. Example 18. Synthesis of 5-(4-butoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.17, TRX-0053). The yield was 0.019 g (15%). Tm=205-207 °C. HRMS (ESI) found for С14H20N4O [M+H+] 261.1710 Da, calculated 261.1710 Da. 1H NMR (300 MHz, DMSO) δ 8.32 (br.s, 3H), 8.06 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 8.8 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 3.33 – 3.12 (m, 4H), 1.76 – 1.65 (m, 2H), 1.50 – 1.37 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, DMSO) δ 160.4, 155.7, 155.6, 128.1, 119.2, 114.9, 67.4, 36.8, 30.6, 24.4, 18.7, 13.7. Example 19. Synthesis of 5-(4-((2-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.18, TRX-0054). The yield was 0.023 g (15%). Tm=232-235 ^C. HRMS (ESI) found for С17H17FN4O [M+H+] 313.1459 Da, calculated 313.1459 Da. 1H NMR (300 MHz, DMSO) δ 8.16 (br.s, 3H), 8.06 – 8.00 (m, 2H), 7.59 (t, J = 7.0 Hz, 1H), 7.49 – 7.40 (m, 1H), 7.32 – 7.17 (m, 4H), 5.22 (s, 2H), 3.31 – 3.19 (m, 2H), 3.17 – 3.08 (m, 2H). 13C NMR (75 MHz, DMSO) δ 160.5 (d, J = 246.2 Hz), 159.5, 156.6, 156.4, 130.9 (d, J = 4.0 Hz), 130.6 (d, J = 8.2 Hz), 127.8, 124.6 (d, J = 3.4 Hz), 123.4 (d, J = 14.5 Hz), 120.8, 115.5 (d, J = 21.0 Hz), 115.1, 63.8, 37.1, 24.7.
Example 20. Synthesis of 5-(4-((3-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.19, TRX-0055). The yield was 0.051 g (31%). Tm=214-216 ^C. HRMS (ESI) found for С17H17FN 4O [M+H+] 313.1459 Da, calculated 313.1459 Da. 1H NMR (300 MHz, DMSO) δ 8.20 (br.s, 3H), 8.08 – 8.02 (m, 2H), 7.51 – 7.40 (m, 1H), 7.35 – 7.28 (m, 2H), 7.23 – 7.13 (m, 3H), 5.21 (s, 2H), 3.32 – 3.20 (m, 2H), 3.18 – 3.10 (m, 2H). 13C NMR (75 MHz, DMSO) δ 162.7 (d, J = 243.6 Hz), 160.1, 156.8, 156.6, 140.1 (d, J = 7.5 Hz), 131.0 (d, J = 8.3 Hz), 128.3, 124.1 (d, J = 1.6 Hz), 120.9, 115.8, 115.2 (d, J = 21.0 Hz), 114.8 (d, J = 21.7 Hz), 69.0, 37.5, 25.0. Example 21. Synthesis of 5-(4-((4-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.20, TRX-0056). The yield was 0.070 g (46%). Tm=220.5-222 °C. HRMS (ESI) found for С17H17FN4O [M+H+] 313.1459 Da, calculated 313.1459 Da. 1H NMR (300 MHz, DMSO) δ 8.20 (s, 3H), 8.08 – 8.01 (m, 2H), 7.53 (dd, J = 8.6, 5.6 Hz, 2H), 7.28 – 7.15 (m, 4H), 5.17 (s, 2H), 3.32 – 3.20 (m, 2H), 3.18 – 3.09 (m, 2H). 13C NMR (75 MHz, DMSO) δ 162.3 (d, J = 243.8 Hz), 160.4, 156.3, 156.2, 133.4 (d, J = 3.0 Hz), 130.6 (d, J = 8.3 Hz), 128.5, 120.3, 115.8 (d, J = 21.4 Hz), 115.8, 69.2, 37.3, 24.9. Example 22. Synthesis of 5-(3-methyl-4-((3-fluorobenzyl)oxy)phenyl)-4H-1,2,4- triazole)-3-ethanamine hydrochloride (1.21, TRX-0057). The yield was 0.053 g (32%). Tm=215- 216 °C. HRMS (ESI) found for С18H19FN4O [M+H+] 327.1616 Da, calculated 327.1616 Da. 1H NMR (300 MHz, DMSO) δ 8.19 (br.s, 3H), 7.97 – 7.89 (m, 2H), 7.51 – 7.42 (m, 1H), 7.37 – 7.28 (m, 2H), 7.22 – 7.13 (m, 2H), 5.24 (s, 2H), 3.33 – 3.19 (m, 2H), 3.18 – 3.09 (m, 2H), 2.28 (s, 3H).13C NMR (75 MHz, DMSO) δ 163.2 (d, J = 243.6 Hz), 159.2, 156.1, 155.8, 140.8 (d, J = 7.4 Hz), 131.5 (d, J = 8.3 Hz), 129.8, 127.9, 126.9, 124.2 (d, J = 2.7 Hz), 119.1, 115.6 (d, J = 20.9 Hz), 114.9 (d, J = 21.9 Hz), 113.1, 69.5, 37.6, 25.1, 17.1. Example 23. Synthesis of 5-(3-methyl-4-((4-fluorobenzyl)oxy)phenyl)-4H-1,2,4- triazole)-3-ethanamine hydrochloride (1.22, TRX-0058). The yield was 0.020 g (12%). Tm=182- 183°C. HRMS (ESI) found for С18H19FN4O [M+H+] 327.1616 Da, calculated 327.1616 Da. 1H NMR (300 MHz, DMSO) δ 8.12 (br.s, 3H), 7.90 – 7.85 (m, 2H), 7.57 – 7.48 (m, 2H), 7.28 – 7.14 (m, 3H), 5.18 (s, 2H), 3.30 – 3.15 (m, 2H), 3.12 – 3.04 (m, 2H), 2.24 (s, 3H).13C NMR (75 MHz, DMSO) δ 161.6 (d, J = 243.6 Hz), 157.5, 156.7, 156.4, 133.1 (d, J = 3.0 Hz), 129.5 (d, J = 8.3 Hz), 128.2, 126.5, 125.1, 120.2, 115.1 (d, J = 21.4 Hz), 111.9, 68.5, 37.0, 24.6, 16.0. Example 24. Synthesis of 5-(4-(4-methoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-
ethanamine hydrochloride (1.23, TRX-0059). The yield was 0.065 g (50%). Tm=300-301 ^C. HRMS (ESI) found for С17H18N4O [M+H+] 295.1553 Da, calculated 295.1553 Da. 1H NMR (300 MHz, DMSO) δ 8.23 (br.s, 3H), 8.13 (d, J = 8.2 Hz, 2H), 7.84 – 7.76 (m, 2H), 7.74 – 7.67 (m, 2H), 7.05 (d, J = 8.5 Hz, 2H), 3.81 (s, 3H), 3.33 – 3.22 (m, 2H), 3.20 – 3.12 (m, 2H). 13C NMR (75 MHz, DMSO) δ 159.5, 157.0, 156.6, 141.3, 131.6, 128.0, 126.9, 126.7, 126.6, 114.7, 55.4, 37.2, 24.7. Example 25. Synthesis of 5-(4-(4-trifluoromethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.24, TRX-0060). The yield was 0.060 g (35%). Tm=299-300 °C. HRMS (ESI) found for С17H15F3N4O [M+H+] 349.1271 Da, calculated 349.1271 Da. 1H NMR (300 MHz, DMSO) δ 8.25 (br.s, 3H), 8.17 (d, J = 8.3 Hz, 2H), 7.87 (t, J = 8.1 Hz, 4H), 7.48 (d, J = 8.3 Hz, 2H), 3.34 – 3.22 (m, 2H), 3.21 – 3.13 (m, 2H).13C NMR (75 MHz, DMSO) δ 157.3, 156.6, 148.1, 140.0, 138.7, 128.8, 128.3, 127.5, 126.9, 121.7, 120.3 (d, J = 256.3 Hz), 37.2, 24.6. Example 26. Synthesis of 5-(4-(3-fluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.25, TRX-0061). The yield was 0.040 g (26%). Tm=260-262 ^C. HRMS (ESI) found for С16H15FN4 [M+H+] 283.1354 Da, calculated 283.1354 Da. 1H NMR (300 MHz, DMSO) δ 8.20 (br.s, 3H), 8.15 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.2 Hz, 2H), 7.67 – 7.47 (m, 3H), 7.29 – 7.18 (m, 1H), 3.33 – 3.21 (m, 2H), 3.19 – 3.10 (m, 2H). 13C NMR (75 MHz, DMSO) δ 163.1 (d, J = 243.4 Hz), 157.4, 156.7, 142.1 (d, J = 8.0 Hz), 140.3, 131.4 (d, J = 8.4 Hz), 128.7, 127.8, 127.1, 123.2 (d, J = 2.4 Hz), 115.1 (d, J = 21.4 Hz), 113.9 (d, J = 22.2 Hz), 37.4, 25.0. Example 27. Synthesis of 5-(4-(2,4-difluorophenyl)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.26, TRX-0062). The yield was 0.059 g (44%). Tm=251-253 °C. HRMS (ESI) found for С16H14F2N4 [M+H+] 301.1259 Da, calculated 301.1259 Da. 1H NMR (300 MHz, DMSO) δ 8.12 (m, 5H), 7.73 – 7.60 (m, 3H), 7.45 – 7.34 (m, 1H), 7.29 – 7.18 (m, 1H), 3.32 – 3.20 (m, 2H), 3.18 – 3.09 (m, 2H). 13C NMR (75 MHz, DMSO) δ 162.0 (dd, J = 208.5, 12.3 Hz), 158.7 (dd, J = 210.1, 12.4 Hz), 156.4, 155.7, 135.5, 131.8 (dd, J = 9.7, 4.6 Hz), 129.1 (d, J = 2.7 Hz), 127.6, 126.2, 123.9 (dd, J = 13.1, 3.8 Hz), 112.1 (dd, J = 21.1, 3.6 Hz), 104.7 (t, J = 26.6 Hz), 36.7, 24.2. Example 28. Synthesis of 5-(4-(4-chlorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride (1.27, TRX-0063). The yield was 0.047 g (36%). Tm=247-249 °C. HRMS (ESI) found for С16H15ClN4 [M+H+] 299.1058 Da, calculated 299.1058 Da. 1H NMR (300 MHz, DMSO) δ 8.23 – 8.09 (m, 5H), 7.87 – 7.74 (m, 4H), 7.58 – 7.51 (m, 2H), 3.32 – 3.20 (m, 2H), 3.18 – 3.09 (m, 2H). 13C NMR (75 MHz, DMSO) δ 157.1, 156.4,
139.1, 138.0, 132.7, 129.0, 128.4, 128.1, 127.0, 126.7, 37.0, 24.6. Example 29. Synthesis of 5-(4-(3,4-dimethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.28, TRX-0064). The yield was 0.046 g (32%). Tm=199-201°C. HRMS (ESI) found for С18H20N4O2 [M+H+] 325.1659 Da, calculated 325.1659 Da. 1H NMR (300 MHz, DMSO) δ 8.28 (br.s, 3H), 8.16 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.4 Hz, 2H), 7.33 – 7.27 (m, 2H), 7.08 – 7.03 (m, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.35 – 3.25 (m, 2H), 3.23 – 3.16 (m, 2H). 13C NMR (75 MHz, DMSO) δ 156.2, 155.9, 149.2, 149.1, 141.8, 131.8, 126.8, 126.7, 125.8, 119.1, 112.3, 110.4, 55.8, 55.7, 36.9, 24.5. Example 30. Synthesis of 5-(4-(3,5-difluorophenyl)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.29, TRX-0065). The yield was 0.050 g (38%). Tm=260-262°C. HRMS (ESI) found for С16H14F2N4 [M+H+] 301.1259 Da, calculated 301.1259 Da. 1H NMR (300 MHz, DMSO) δ 8.32 (br.s, 3H), 8.22 – 8.17 (m, 2H), 7.95 – 7.90 (m, 2H), 7.59 – 7.49 (m, 2H), 7.31 – 7.22 (m, 1H), 3.35 – 3.16 (m, 4H). 13C NMR (75 MHz, DMSO) δ 162.2 (dd, J = 205.6, 12.3 Hz), 158.9 (dd, J = 207.4, 12.3 Hz), 157.5, 156.3, 135.3, 131.9 (dd, J = 9.7, 4.7 Hz), 129.2 (d, J = 2.9 Hz), 128.5, 126.2, 124.2 (dd, J = 13.3, 3.8 Hz), 112.2 (dd, J = 21.2, 3.6 Hz), 104.6 (dd, J = 26.9, 25.9 Hz), 37.0, 24.6. Example 31. Synthesis of 5-(3-(4-trifluoromethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.30, TRX-0066). The yield was 0.045 g (28%). Tm=253-257 °C. HRMS (ESI) found for С17H15F3N4O [M+H+] 349.1271 Da, calculated 349.1271 Da. 1H NMR (300 MHz, DMSO) δ 8.38 – 8.35 (m, 1H), 8.18 (br.s, 3H), 8.09 – 8.04 (m, 1H), 7.91 – 7.85 (m, 2H), 7.82 – 7.77 (m, 1H), 7.66 – 7.59 (m, 1H), 7.53 – 7.47 (m, 2H), 3.31 – 3.21 (m, 2H), 3.18 – 3.11 (m, 2H). 13C NMR (75 MHz, DMSO) δ 157.1, 156.5, 148.1 (q, J = 1.7 Hz), 139.4, 138.8, 129.8, 129.4, 128.8, 128.2, 125.5, 124.4, 121.6, 120.2 (q, J = 256.4 Hz), 37.0, 24.6. Example 32. Synthesis of 5-(4-(4-methylphenoxy)phenyl)-4H-1,2,4-triazole)-3- ethanamine hydrochloride (1.31, TRX-0067). The yield was 0.030 g (13%). Tm=234.5-236 °C. HRMS (ESI) found for С17H18N4O [M+H+] 295.1553 Da, calculated 295.1553 Da. 1H NMR (300 MHz, DMSO) δ 8.16 (br.s, 3H), 8.06 – 8.00 (m, 2H), 7.28 – 7.21 (m, 2H), 7.09 – 6.96 (m, 4H), 3.30 – 3.19 (m, 2H), 3.16 – 3.07 (m, 2H), 2.31 (s, 3H). 13C NMR (75 MHz, DMSO) δ 158.9, 156.7, 156.3, 153.3, 133.5, 130.7, 128.1, 122.9, 119.6, 117.9, 37.0, 24.6, 20.4. Example 33. Construction of expression plasmids, TAAR and stably transfected cell lines. Materials and methods. The pchTAAR1 expression vector containing the human TAAR1 receptor gene was obtained for conducting experiments. The expression vector pcEPAC was used to explore
changes in cAMP concentrations in cells in response to the action of various chemical compounds. It provides constitutive expression of the Rluc-EPAC-YFP fused gene, the product of which is a biosensor for monitoring the activation of Gαs signaling pathway. It is based on cAMP-dependent factor EPAC1 (Exchange protein activated by cAMP 1) which changes its conformation in response to binding of cAMP molecule. Donor (Rluc) and acceptor (YFP) molecules are located in close proximity in an inactive form, however, when the biosensor binds to cAMP they move significantly away from each other (Barak et al., 2008). Consequently, a decrease in resonance energy transfer from the donor to the acceptor is observed. This is expressed mathematically as the ratio between acceptor luminescence intensity (535 nm) and donor luminescence intensity (480 nm) or the so-called BRET ratio (BRET ratio). Therefore, upon activation of Gαs signaling pathway, which occurs when the receptor under study is activated by a ligand, a decrease in the BRET ratio will be observed. To perform BRET HEK293T cell culture (ATCC#CRL-3216) was grown in DMEM medium (Gibco) containing 4.5 g/L glucose until about 70–90% confluence was reached. Next, cells grown on 10 cm Petri dish were co-transfected with two expression vectors: pchTAAR1 (3– 5 µg) and pcEPAC (3–5 µg) using Lipofectamine 2000 (Invitrogen) according to the standard protocol. The same amount of «empty» pcDNA3.1(+) vector was used as a negative control instead of the pchTAAR1 vector to assess non-specific interaction. After lipofection (conducted for 4 hours) the cells were removed from the dish, suspended in MEM medium without phenol red (Gibco) containing 2% of fetal bovine serum, and transferred to 96-well plate pretreated with 0.0001% poly-D-lysine solution at 100,000-150,000 cells per well. Cells were grown on plates for 24–48 hours. The culture medium was then carefully aspirated, and 70 µl of PBS buffer containing Ca2+ and Mg2+ ions, 10 µl of 2 mM IBMX solution (Sigma) and 10 µl of 50 µM coelenterazine h solution (Promega) were sequentially added to each well. The plate was incubated for 10 min at room temperature. Next, in order to determine the effective concentration (ЕС50) ligand solutions diluted from 0.1 nM to 10 μM were added and incubated for another 5 minutes at room temperature. A non-selective agonist of β2-adrenergic receptor, isoprotenerol (assessment of biosensor performance), at a concentration of 100 nM, as well as beta- phenylethylamine (a natural agonist of TAAR1 receptor) at concentrations 0.1 nM to 10 μM were used as positive controls. All compounds were tested in 3 replicates. Thereafter, the plate was placed in a reader, and values of luminescence intensity were read for 20 minutes with maxima at wavelengths of 535 and 480 nm. The BRET ratio was then calculated mathematically, dose-response curves were built, and the effective ligand concentration was determined. Data on the effective ligand concentration are presented in Table 1.
Table 1. TAAR1 receptor activation by compounds 1.1 – 1.31
Therefore, it can be concluded based on the data obtained that the compounds of formula 1 according to the present invention have excellent agonistic activity on TAAR1 receptor and can be used to treat diseases mediated by trace amine receptors TAAR1 such as mental disorders, cognitive disorders, neurological and neurodegenerative diseases, schizophrenia, depression, bipolar disorder, attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, Parkinson’s disease, dementia (including Alzheimer’s disease), epilepsy, migraine, high blood pressure (hypertension), alcohol or drug abuse, nicotine addiction, obesity, diabetes, metabolic disorder, disorder associated with energy consumption and expenditure, disorder associated with impaired body temperature homeostasis, sleep and circadian rhythm disorder, and cardiovascular disorder. References: 1. Borowsky, B., Adham, N., Jones, K. A., Raddatz, R., Artymyshyn, R., Ogozalek, K. L., Gerald, C. (2001). Trace amines: Identification of a family of mammalian G protein- coupled receptors. Proc Natl Acad Sci U S A 98, 8966–8971. 2. Bunzow, J. R., Sonders, M. S., Arttamangkul, S., Harrison, L. M., Zhang, G., Quigley, D. I., Grandy, D. K. (2001). Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60, 1181–1188. 3. Sotnikova, T. D., Zorina, O. I., Ghisi, V., Caron, M. G., & Gainetdinov, R. R. (2008). Trace amine associated receptor 1 and movement control. Parkinsonism Relat Disord 14(Suppl.2), S99–102. 4. Lindemann, L., & Hoener, M. C. (2005). A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 26, 274–281. 5. Revel, F. G., Moreau, J. L., Gainetdinov, R. R., Bradaia, A., Sotnikova, T. D., Mory, R., Hoener, M. C. (2011). TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl
Acad Sci U S A 108, 8485–8490. 6. Revel, F. G., Moreau, J. L., Gainetdinov, R. R., Ferragud, A., Velazquez-Sanchez, C., Sotnikova, T. D., Hoener, M. C. (2012). Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry 72, 934–942. 7. Lam V. M., Espinoza S., Gerasimov A. S., Gainetdinov R. R., Salahpour A. (2015). In-vivo pharmacology of trace-amine associated receptor 1. Eur. J. Pharmacol. 763 (Pt B), 136–142.
Claims
CLAIMS 1. A compound of formula 1 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease, disorder or condition mediated by trace amine receptors TAAR1, wherein the compound of formula 1 is:
Formula 1 where R is: С6-С14 aryl optionally substituted with 1-2 substituents selected from the group consisting of: С1-С10 alkyl optionally substituted with 1-3 halogen atoms, С1-С10 alkoxy optionally substituted with 1-3 halogen atoms or С6-С14 aryl optionally substituted with a halogen atom, С6-С14 aryl optionally substituted with 1-2 substituents selected from the group including halogen and С1-С10 alkoxy optionally substituted with 1-3 halogen atoms, a halogen, amino group of formula -N(R1)2 where each R1 is independently hydrogen or С1-С10 alkyl, nitro group, and C6-C14 aryloxy optionally substituted with С1-С10 alkyl; or 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen or sulfur.
2. The compound of claim 1, wherein R is С6-С14 aryl substituted with 1-2 substituents selected from the group including methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy and phenyloxy optionally substituted with С1-С10 alkyl.
3. The compound of claim 1, wherein R is С6-С14 aryl substituted with С6-С14 aryl optionally substituted with 1-2 substituents selected from the group including halogen, methoxy, ethoxy, propoxy, butoxy and trifluoromethoxy.
4. The compound of claim 1, wherein R is С6-С14 aryl substituted with 1-2 substituents selected from the group including methyl, ethyl, propyl, butyl and trifluoromethyl.
5. The compound of claim 1, wherein R is С6-С14 aryl substituted with 1-2 substituents selected from the group including fluoride, chloride and bromide.
6. The compound of claim 1, wherein R is С6-С14 aryl substituted with an amino group selected from the group including methylamino, dimethylamino and diethylamino.
7. The compound of claim 1, wherein R is thiophene.
8. The compound of claim 1, wherein the compound of formula 1 is selected from the group including: 5-(3-methoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3-trifluoromethylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-trifluoromethoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(2-thiophene)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(benzyloxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3-bromophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3,5-dichlorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(phenyl-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(2-methylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-ethoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-chlorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(2-bromophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(dimethylamino)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3,5-dimethylphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-fluorophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3-nitrophenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-butoxyphenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-((2-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-((3-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-((4-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3-methyl-4-((3-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3-methyl-4-((4-fluorobenzyl)oxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(4-methoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(4-trifluoromethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(3-fluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(2,4-difluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(4-chlorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(3,4-dimethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(4-(3,5-difluorophenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride; 5-(3-(4-trifluoromethoxyphenyl)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride;
5-(4-(4-methylphenoxy)phenyl)-4H-1,2,4-triazole)-3-ethanamine hydrochloride.
9. The compound of claim 1, wherein the disease, disorder or condition is selected from the group including a mental disorder, a cognitive disorder, a metabolic disorder, a neurological disorder and a neurodegenerative disorder.
10. The compound of claim 1, wherein the disease, disorder or condition is selected from the group including depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-induced disorder, psychosis, schizophrenia, obsessive-compulsive disorder, Parkinson’s disease, Alzheimer’s disease, epilepsy, migraine, high blood pressure, alcohol or drug abuse, nicotine addiction, eating disorder, diabetes, diabetes complications, obesity, dyslipidemia, disorders associated with energy consumption and expenditure, disorders associated with impaired body temperature homeostasis, sleep and circadian rhythm disorder, and cardiovascular disorder.
11. A pharmaceutical composition for use in the treatment of a disease, disorder or condition mediated by trace amine receptors TAAR1 comprising a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the compound of formula 1 is:
Formula 1 where R is: С6-С14 aryl optionally substituted with 1-2 substituents selected from the group consisting of: С1-С10 alkyl optionally substituted with 1-3 halogen atoms, С1-С10 alkoxy optionally substituted with 1-3 halogen atoms or С6-С14 aryl optionally substituted with a halogen atom, С6-С14 aryl optionally substituted with 1-2 substituents selected from the group including halogen and С1-С10 alkoxy optionally substituted with 1-3 halogen atoms, halogen, amino group of formula -N(R1)2 where each R1 is independently hydrogen or С1-С10 alkyl, nitro group, and C6-C14 aryloxy optionally substituted with С1-С10 alkyl; or 5-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen or
sulfur.
12. The pharmaceutical composition of claim 11, wherein the excipient is selected from the group including a pharmaceutically acceptable carrier, diluent, filler and solvent.
13. The pharmaceutical composition of claim 11 or claim 12, wherein the disease, disorder or condition is selected from the group including a mental disorder, a cognitive disorder, a metabolic disorder, a neurological disease and a neurodegenerative disease.
14. The pharmaceutical composition of claim 11 or claim 12, wherein the disease, disorder or condition is selected from the group including depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-induced disorder, psychosis, schizophrenia, obsessive-compulsive disorder, Parkinson’s disease, Alzheimer’s disease, epilepsy, migraine, high blood pressure, alcohol or drug abuse, nicotine addiction, eating disorder, diabetes, diabetes complications, obesity, dyslipidemia, disorders associated with energy consumption and expenditure, disorders associated with impaired body temperature homeostasis, sleep and circadian rhythm disorder and cardiovascular disorder.
15. The pharmaceutical composition of any one of claims 11-14, wherein the pharmaceutical composition is present as a dosage form selected from the group including tablet, powder, granule, pill, suspension, pellet, capsule, sachet and injectable solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA202192214 | 2021-09-01 | ||
EA202192214 EA043874B1 (en) | 2021-09-01 | SUBSTITUTED 2-(5-ARYL-4H-1,2,4-TRIAZOL-3-YL)ETHANAMINES AS MODULATORS OF TRACE AMINE ASSOCIATED RECEPTOR 1 (TAAR1) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023033681A1 true WO2023033681A1 (en) | 2023-03-09 |
WO2023033681A4 WO2023033681A4 (en) | 2023-05-19 |
Family
ID=83690035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2022/050272 WO2023033681A1 (en) | 2021-09-01 | 2022-09-01 | Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023033681A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008046757A1 (en) | 2006-10-19 | 2008-04-24 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
WO2008052907A1 (en) | 2006-11-02 | 2008-05-08 | F. Hoffmann-La Roche Ag | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
CA2856204A1 (en) | 2012-01-12 | 2013-07-18 | F. Hoffmann-La Roche Ag | Heterocyclic derivatives as trace amine associated receptors (taars) |
WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
WO2016016292A1 (en) | 2014-08-01 | 2016-02-04 | F. Hoffmann-La Roche Ag | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives |
-
2022
- 2022-09-01 WO PCT/RU2022/050272 patent/WO2023033681A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008046757A1 (en) | 2006-10-19 | 2008-04-24 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
WO2008052907A1 (en) | 2006-11-02 | 2008-05-08 | F. Hoffmann-La Roche Ag | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
CA2856204A1 (en) | 2012-01-12 | 2013-07-18 | F. Hoffmann-La Roche Ag | Heterocyclic derivatives as trace amine associated receptors (taars) |
WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
WO2016016292A1 (en) | 2014-08-01 | 2016-02-04 | F. Hoffmann-La Roche Ag | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives |
Non-Patent Citations (8)
Title |
---|
BERGE S.M ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
BOROWSKY, B.ADHAM, N.JONES, K. A.RADDATZ, R.ARTYMYSHYN, R.OGOZALEK, K. L.GERALD, C.: "Trace amines: Identification of a family of mammalian G protein-coupled receptors", PROC NATL ACAD SCI U S A, vol. 98, 2001, pages 8966 - 8971, XP002185201, DOI: 10.1073/pnas.151105198 |
BUNZOW, J. RSONDERS, M. SARTTAMANGKUL, S.HARRISON, L. M.ZHANG, G.QUIGLEY, D. IGRANDY, D. K.: "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor", MOL PHARMACOL, vol. 60, 2001, pages 1181 - 1188, XP008008060 |
LAM V. M., ESPINOZA S., GERASIMOV A. S., GAINETDINOV R. R., SALAHPOUR A.: "In-vivo pharmacology of trace-amine associated receptor 1.", EUR. J. PHARMACOL., vol. 763, 2015, pages 136 - 142 |
LINDEMANN, L.HOENER, M. C.: "A renaissance in trace amines inspired by a novel GPCR family", TRENDS PHARMACOL SCI, vol. 26, 2005, pages 274 - 281, XP002498588, DOI: 10.1016/j.tips.2005.03.007 |
REVEL, F. G.MOREAU, J. L.GAINETDINOV, R. R.BRADAIA, A.SOTNIKOVA, T. DMORY, RHOENER, M. C: "TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity", PROC NATL ACAD SCI U S A, vol. 108, 2011, pages 8485 - 8490, XP055710233, DOI: 10.1073/pnas.1103029108 |
REVEL, F. G.MOREAU, J. L.GAINETDINOV, R. R.FERRAGUD, A.VELAZQUEZ-SANCHEZ, C.SOTNIKOVA, T. D.HOENER, M. C.: "Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics", BIOL PSYCHIATRY, vol. 72, 2012, pages 934 - 942 |
SOTNIKOVA, T. D., ZORINA, O. I., GHISI, V., CARON, M. G., & GAINETDINOV, R. R.: "Trace amine associated receptor 1 and movement control", PARKINSONISM RELAT DISORD, vol. 14, 2008, pages 99 - 102 |
Also Published As
Publication number | Publication date |
---|---|
WO2023033681A4 (en) | 2023-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5451602B2 (en) | 5-Heteroaryl-substituted indazoles as kinase inhibitors | |
TW593278B (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
EP2651887B1 (en) | N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders | |
EP3190109A1 (en) | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | |
JP5315244B2 (en) | Use of azabicyclohexane derivatives | |
TW200418830A (en) | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | |
JP2008510768A (en) | Sigma receptor inhibitor | |
KR101738866B1 (en) | Cyclic N,N'-diarylthioureas and N,N'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
EP1023061A1 (en) | Somatostatin agonists | |
KR101107807B1 (en) | 2-aminoquinolines as 5-ht5a receptor antagonists | |
EP3558983A1 (en) | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions | |
WO2014001279A1 (en) | A phenyl triazole derivative and its use for modulating the gabaa receptor complex | |
TW201345904A (en) | Novel 1-substituted indazole derivatives | |
EA016592B1 (en) | Tricyclic isoquinoline derivatives for treatment of obesity | |
BR112019011758A2 (en) | azacyclobutyl triazole derivative of condensed ring group, method of preparation thereof and use thereof in medicine | |
WO2014001278A1 (en) | A phenyl triazole derivative and its use for modulating the gabaa receptor complex | |
CZ9302010A3 (en) | DERIVATIVE OF 4-AMINO-1,3,4,5/TETRAHYDROBENZ(cd)INDOLE SUBSTITUTED IN POSITION 6 BY A HETEROCYCLIC GROUP, PROCESS OF ITS PREPARATION AND A PHARMACEUTICAL PREPARATION IN IT IS COMPRISED | |
WO2023033681A1 (en) | Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1) | |
JP2001520225A (en) | Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists | |
EP1648891A1 (en) | Sulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands | |
JP2018531263A (en) | Oxadiazaspiro compounds with activity against pain | |
JP2018531263A6 (en) | Oxadiazaspiro compounds with activity against pain | |
EP3365338B1 (en) | Substituted morpholine derivatives having activity against pain | |
EA043874B1 (en) | SUBSTITUTED 2-(5-ARYL-4H-1,2,4-TRIAZOL-3-YL)ETHANAMINES AS MODULATORS OF TRACE AMINE ASSOCIATED RECEPTOR 1 (TAAR1) | |
US7534801B2 (en) | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22789351 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |